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III Summary 
Pulmonary arterial hypertension (PAH) is characterised by selective elevation of 
pulmonary arterial pressure. The pathological hallmark of PAH is the occlusion of 
pulmonary arterioles due to proliferation and dysfunction of smooth muscle and 
endothelial cells. Heterozygous mutations in BMPR2, encoding the type II BMP receptor 
(BMPRII), were identified in PAH suggesting that alterations to BMPRII function are 
involved in disease onset and/or progression. 
To further elucidate the function of BMPRII, we sought to identify novel 
interaction partners of BMPRII by yeast two-hybrid analysis using the kinase domain of 
BMPRII as a bait. Using this technology, several novel interaction partners of BMPRII 
were identified. Among these, the receptor for activated protein kinase C (RACK)-1 was 
selected for further investigation. The interaction between RACK1 and the BMPRII 
kinase domain was confirmed by Glutathione S-transferase (GST)-pull-down and co-
immunoprecipitation. Immunofluorescent staining of human pulmonary artery smooth 
muscle cells (paSMC), as well immunohistochemistry of human lungs from healthy 
donors and PAH patients, demonstrated the co-localisation of BMPRII and RACK1 in 
vitro and in vivo. Overexpression of RACK1 in paSMC led to a two-fold increase in 
induction of a BMP-responsive promoter in a luciferase-based promoter reporter assay, 
indicating that the BMPRII-RACK1 interaction may potentiate BMP signalling. RACK1 
depletion using small interfering RNA (siRNA) technology resulted in enhanced 
proliferation of paSMC, thus implicating a role for RACK1 and the RACK1-BMPRII 
interaction in paSMC growth regulation. In contrast, overexpression of RACK1 led to 
enhanced proliferation of paSMC. 
Several BMPRII variants that contained amino acid substitutions present in PAH 
patients exhibited a reduced affinity for RACK1. Furthermore, in the monocrotaline-
induced rat model of PAH, the expression of RACK1 was significantly down-regulated at 
the RNA and protein level, two and four weeks after monocrotaline administration. 
Thus, the novel interaction of RACK1 with BMPRII is functionally significant in 
BMP signal transduction. The reduced affinity of RACK1 for BMPRII variants that are 
peculiar to PAH patients, and the reduced levels of RACK1 evident in the pulmonary 
vasculature in an animal model of PAH, suggest a potential role for RACK1, and the 
RACK1-BMPRII interaction, in the pathogenesis of PAH.aaaaaaaaaaaaaaaaaaaaaaaaa 
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IV Zusammenfassung 
Die Pulmonalarterielle Hypertonie (PAH) ist charakterisiert durch eine selektive 
Erhöhung des pulmonalarteriellen Blutdrucks. Das pathologische Korrelat der PAH ist 
ein Verschluss der pulmonalen Arteriolen durch eine Proliferation/Fehlfunktion der 
glatten Gefässmuskelzellen und des Endothels. Heterozygote Keimbahnmutationen im 
Bone Morphogenetic Receptor Type II (BMPRII) kodierenden Genlokus zeigen eine 
Assoziation mit PAH, was für einen Einfluss des BMPRII auf die Pathogenese der PAH 
spricht. 
Um die Funktion von BMPRII zu charakterisieren, war es das Ziel unserer Arbeit, 
neue potentielle Interaktionspartner dieses Rezeptors mittels Yeast Two-Hybrid Analyse 
zu identifizieren. Unter den vielen bisher unbekannten Interaktionspartnern von BMPRII 
wurde RACK (receptor for activated protein kinase C)-1 für weitergehende 
Untersuchungen ausgewählt. Glutathion S-Transferase (GST)-pulldown Experimente 
sowie Ko-Immunopräzipitationen bestätigten die Interaktion von RACK1 und der BMPRII 
Kinasedomäne. Immunohistochemische Analysen von Lungenschnitten und 
Immunofluoreszenzanalysen isolierter glatter Muskelzellen aus der Pulmonalarterie 
zeigten eine Ko-Lokalisation von BMPRII und RACK1 in vitro und in vivo. Für weitere 
funktionelle Analysen wurde das RACK1 Gen kloniert und in einem BMP-
Reportergenassay überexprimiert. RACK1 Expression führte zu einer zweifach erhöhten 
Reportergenaktivität nach BMP-2 Stimulation, was einen synergistischen Einfluss der 
BMPRII-RACK1 Interaktion auf die BMP Signalkaskade zeigt. Dieser Befund wird durch 
die Tatsache unterstüzt, dass die Depletion von RACK1 mittels small interfering RNA 
(siRNA) Technologie zu einer verstärkten Proliferation von glatten Gefässmuskelzellen 
der A. Pulmonalis führt, was für eine regulatorische Rolle von RACK1 auf das 
Zellwachstum spricht.  
Mehrere BMPRII Varianten, welche aus dem internationalen PAH Patientenpool 
stammen, zeigten eine reduzierte Affinität für RACK1. Im Tiermodell der durch 
Monokrotalin induzierten pulmonalen Hypertonie wurde eine signifikant erniedrigte 
Expression von RACK1 auf RNA und Proteinebene gefunden. 
Die vorliegende Arbeit beschreibt daher einen funktionell bedeutenden Einfluss 
der neu identifizierten Interaktion zwischen BMPRII und RACK1 auf die BMP 
Signaltransduktion. Die reduzierte Affinität von RACK1 für BMPRII Varianten und die 
erniedrigte RACK1 Expression im Tiermodell der pulmonalen Hypertonie sprechen für 
einen bedeutenden Einfluss von RACK1 und der RACK1-BMPRII Interaktion auf die 
Pathogenese  der PAH.aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa   
Introduction          1 
1 Introduction 
1.1 Pulmonary arterial hypertension 
1.1.1 Characteristics of pulmonary arterial hypertension 
Pulmonary arterial hypertension (PAH) is a progressive disease characterised by 
elevated pulmonary vascular resistance, which results in diminished right heart function 
due to increased right ventricular afterload. Clinically, PAH is defined as an elevation in 
the mean pulmonary arterial pressure of at least 25 mm Hg at rest, or greater than   
30 mm Hg during exercise; while in healthy adults it does not exceed 12-16 mm Hg. 
Gradual clinical deterioration occurs when the mean pulmonary artery pressure plateaus 
at 60-70 mm Hg, and cardiac output progressively declines (Rich et al., 1987). The 
symptoms of PAH are largely non-specific, but may include shortness of breath, chest 
pain, syncope, fatigue, and peripheral oedema (Gaine and Rubin 1998; Strange et al., 
2002). 
This rare disorder with an estimated incidence of two to three cases per million 
(per year) worldwide, occurs most commonly in young and middle-aged women but is 
fatal, with a mean survival of two to three years after onset of symptoms (McLaughlin et 
al., 2002). The pathogenesis of IPAH remains poorly understood, although 
vasoconstriction is believed to be an early component in the development of the disease. 
Excessive vasoconstriction has been correlated with abnormal function or expression of 
potassium channels, as well as endothelial dysfunction, which subsequently leads to 
chronically impaired production of vasodilators such as nitric oxide and prostacyclin, 
along with overexpression of vasoconstrictors such as endothelin (ET)-1 (see Figure 1.1) 
(Humbert et al., 2004). Exposure to a variety of stimuli, including high-altitude hypoxia, 
appetite suppressants, monocrotaline extracts, inhaled solvents, cocaine, and infections 
(particularly with human immunodeficiency virus (HIV)) may also trigger an initial 
inflammatory response that may lead to PAH (Cheever 2005). Genetic predisposition 
may also direct the activity of pulmonary artery fibroblasts, smooth muscle cells (SMC), 
and endothelial cells, as well as platelets and leukocytes or their specific interactions 
with different extrinsic factors, that lead to the development of PAH (Humbert et al., 
2004). 
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Figure 1.1  Interaction between genetic and extrinsic factors that lead to PAH    
(after Strange et al., 2002).  
 
A recent classification of PAH is based on the aetiology of the various forms of 
this disease, and three principle categories of PAH have been identified: idiopathic 
pulmonary arterial hypertension (IPAH), familial pulmonary arterial hypertension (FPAH) 
and pulmonary arterial hypertension related to associated conditions (APAH). In the 
case of the latter, associated conditions include connective tissue disease, congenital 
heart defects, HIV infection and thromboembolic diseases (Simonneau et al., 2004). 
 
1.1.2 Histopathology of pulmonary arterial hypertension 
The different forms of PAH exhibit similar clinical presentation and functional 
derangement (Pietra 1994; Pietra et al., 2004). Histological changes, common to all 
forms of PAH, affect the pulmonary vasculature and the right ventricle. Pulmonary 
vascular remodelling associated with PAH involves all layers of the vessel wall, resulting 
in remarkable changes in the structure, numbers and function of all cells located in the 
vessel wall (endothelial cells, SMC, and fibroblasts) (see Figure 1.2). These changes 
include cellular hypertrophy, hyperplasia and an increased deposition of structural matrix 
proteins (e.g. collagen and elastin) in the vessel wall. During the development of PAH, a 
narrowing of the vessel lumen caused by intimal proliferation (proliferation of endothelial 
cells), medial thickening (through the hypertrophy and hyperplasia of SMC) and 
adventitial remodelling (via fibroblast proliferation and extracellular matrix deposition) is 
observed. In addition, a hallmark of PAH is the formation of a layer of myofibroblasts and 
extracellular matrix between the endothelium and the internal elastic lamina, termed the 
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neointima. Remodelling also involves the distal extension of SMC into small peripheral 
(normally nonmuscular) pulmonary arteries within the respiratory acinus as well as the 
formation of plexiform lesions. However, the precise composition of plexiform lesions is 
not known. It has been proposed that abnormal monoclonal endothelial cell proliferation, 
in a process of local angiogenesis, leads to occlusion of small arteries. Alternatively, 
plexiform lesions may be formed by transdifferentiation of endothelial cells into SMC 
(Tuder et al., 1994; Durmowicz and Stenmark 1999; Jeffery and Morrell 2002; Mandegar 
et al., 2004).  
    
Donor     PAH     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2  Histopathological changes observed in PAH. 
Pulmonary arterioles in a normal patients (left) and in patients with PAH (right) with significantly 
hypertropic tunica medium (after Eickelberg and Seeger 2005). 
 
 
1.1.3 Genetic basis of pulmonary arterial hypertension 
In the National Institutes of Health (NIH) PAH registry, 6% of affected patients 
were identified as having a familial association with the disease (Rich et al., 1987). In an 
effort to understand the genetic basis of the disease, most studies have focused either 
on the imbalance between vasoconstriction and vasodilatation, or on specific growth 
factors, inflammatory mediators or ion channels (Geraci et al., 2001). 
Mutations in two receptors of the transforming growth factor-beta (TGFβ) 
superfamily are present in majority of cases of FPAH (Lane et al., 2000). Mutations in 
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the exonic regions of the bone morphogenetic protein receptor type 2 (BMPR2) gene are 
found in about 50% of familial cases. Additionally, an activin like kinase type 1 (ALK1) 
gene mutation was found in patients with hereditary haemorrhagic telangiectasia (HHT) 
that was co-existant with PAH (Trembath 2001; Harrison et al., 2003). Furthermore, 
about 10% of patients with sporadic idiopathic IPAH have BMPR2 mutations (Thomson 
et al., 2000). 
The incidence of the BMPR2 mutations in the general population is unknown, but 
is thought to be exceeding low. It is suggested that the 50% of familial cases lacking 
exonic mutations and apparently 90% sporadic cases have either intronic BMPR2 or 
ALK1 polymorphisms, or alterations in the promoter or 5΄ UTR regions of these genes. It 
is also possible that genetic predispositions exist concerning normal variations in genes 
that influence the pulmonary circulation (Newman et al., 2004). 
 
1.1.4 Animal models of pulmonary arterial hypertension 
A number of animal models have been used to gain insight into pathogenesis of 
IPAH, most commonly employing hypoxia or monocrotaline. However none of these 
models reproduce the full spectrum of changes observed in IPAH patients. 
Nevertheless, they have been useful for hypothesis testing. 
 
1.1.4.1 The monocrotaline rat model of pulmonary arterial hypertension 
Monocrotaline (MCT) is a pyrrolizidine alkaloid, which after single administration 
in rats, causes pathologic alterations in the lung and heart comparable to what is 
observed in human PAH: induced neointimal formation, pulmonary arterial hypertension, 
pulmonary vasculitis, right ventricular failure and eventual death. 
The initiating mechanism(s) by which this agent causes these pathological 
changes remain elusive. After administration, monocrotaline is first activated by the liver 
to the electrophile monocrotaline pyrole (MCTP), which has characteristics of a 
bifunctional cross-linking agent, and has a half-life of~3 s in aqueous environments at 
neutral pH. Stabilisation of MCTP by red blood cells facilitates its subsequent transport 
to the lung, where it induces endothelial injury by covalent reactions with cytosolic and 
cytoskeletal proteins. 
An experiment with bovine pulmonary artery endothelial cells demonstrated that 
MCTP can cause a moderate decrease in endothelial permeability and inhibits cell 
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proliferation, due to cell cycle arrest in G2/M phase. Apoptosis has also recently been 
shown to occur in rat pulmonary endothelial cells following the administration of MCT. 
Interestingly, MCT cannot be applied to all rodents, since MCT causes PAH in rats but 
not in mice (Lame et al., 2000; Nishimura et al., 2003). 
 
1.1.4.2 The hypoxia-induced model of pulmonary arterial hypertension 
Hypoxia also plays an important role in the pathology and physiology of the lung. 
During the early period of hypoxic exposure, pulmonary vascular resistance is increased 
due to hypoxic vasoconstriction. However, prolonged exposure to the hypoxic condition 
elevates vascular resistance by causing structural changes in the pulmonary vasculature 
(Kobs et al., 2005). 
Mice exposed to 10% O2 for three weeks develop medial wall hypertrophy within the 
small pulmonary arterioles, pulmonary hypertension, and finally cor pulmonale. Vascular 
remodelling results in increased pulmonary arterial pressure leading to the right heart 
hypertrophy. 
 
1.1.4.3 Transgenic animals 
A functional BMPRII is required for effective BMP signalling, consequently 
BMPR2-/- mice die early in development, before gastrulation; while BMPR2+/- mice 
develop normally and do not exhibit perturbations to pulmonary haemodynamics or 
histological changes indicative of a vascular remodelling event (Beppu et al., 2000). 
To overcome the developmental lethality observed in traditional transgenic 
approaches, and to create a useful model to study the molecular and physiological 
abnormalities in PAH, a conditional, tissue-specific BMPR2 transgenic mouse SM22-tet-
BMPR2delx4+ was created. This mouse conditionally expresses a cDNA encoded a 
dominant-negative BMPRII (West et al., 2004). This dominant-negative BMPRII arises 
from a mutation in the BMPR2 gene that has been identified in patients with FPAH,    
where a T base is inserted at position 504 in the kinase domain of the protein, resulting 
in a premature stop after 18 amino acids into the kinase domain. A tetracycline-
responsive element, and a transactivator gene driven by the smooth muscle-specific 
SM22 promoter in a FVB/N background control expression of this construct. Activation of 
the mutation led to mice recapitulating aspects of the pulmonary hypertensive 
phenotype, including an increase in pulmonary artery pressure, right ventricle-to-left 
ventricle plus septum ratio (RV/LV+S) and pulmonary arterial muscularisation. Intimal 
Introduction          6 
(plexiform) lesions that are observed in PAH patients were absent in SM22-tet-
BMPR2delx4+ mice but it is possible that loss of BMPR2 signalling in endothelium would 
result in this pathology. Additional transgenic mice that utilise an endothelial-specific 
promoter have been constructed to address this possibility (West et al., 2004). 
 
1.2 BMP signalling  
1.2.1 Bone morphogenetic proteins 
Bone morphogenetic proteins (BMP) are a group of secreted polypeptide growth 
factors originally identified as molecules that can induce ectopic bone and cartilage 
formation in rodents (Wozney et al., 1988). More than 20 BMP-related proteins have 
been identified to date, and are subdivided into several groups based on their structure 
and function (Kawabata et al., 1998). One subgroup consists of BMP2, BMP4, and the 
Drosophila decapentaplegic (dpp) gene product (BMP2/4 subgroup), while BMP5, 
BMP6, BMP7 (also termed osteogenic protein-1, OP1), BMP8 (OP2), and the Drosophila 
gbb-60A gene product, form another subgroup (the OP1 group). A third group consists 
of growth-differentiation factor-5 (GDF5), also termed cartilage-derived morphogenetic 
protein-1 (CDMP1), GDF6 (CDMP2 or BMP13), and GDF7 (BMP12). Members of the 
BMP family have distinct expression profiles and different biological activities (Table 
1.1), but all with the exception of the metalloprotease BMP1, are members of the TGFβ 
superfamily. They are produced by, and act on, a wide variety of cell types including 
monocytes, epithelial, mesenchymal, neuronal, pulmonary smooth muscle, and 
endothelial cells, playing complex and multifunctional roles in a variety of tissues in 
addition to bone. Many of them have important functions in the regulation of a broad 
range of biological activities including proliferation, migration, differentiation, matrix 
production and apoptosis during embryogenesis, and throughout adult life (Kawabata et 
al., 1998; Massague and Chen 2000; Massague and Wotton 2000; Miyazono et al., 
2001; Chen et al., 2004).  
The BMPs are conserved broadly across the animal kingdom and like many 
proteins, are synthesised as precursor proteins that are composed of a signal peptide 
containing a prodomain, and a mature domain. The post-translational processing of 
BMPs is important for the secretion of biologically active molecules. After removal of the 
signal peptide, the proproteins undergo dimerisation. As processing proceeds, specific 
proteolytic enzymes cleave the dimerised proteins at a RXXR site, resulting in the 
generation of the biologically active dimeric mature protein. Monomeric proteins contain 
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seven conserved cysteine residues that are involved in folding of the molecules into a 
unique three-dimentional structure called a cysteine knot (Vitt et al., 2001). One-
conserved cysteine residue, which is not involved in cysteine knot formation, builds a 
disulfide bridge between two subunits. This results in the formation of a covalently-linked 
dimer, which is critical for biological activity (Shimasaki et al., 2004). Interestingly, some 
of the BMP ligands can form homodimers but also heterodimers, particularly in the case 
of BMP2, 4, 5, and 7, which exhibit greater biological activity than their corresponding 
homodimers. 
 
Table 1.1  Examples of BMP family members and their proposed functions    
(after Kawabata et al., 1998). 
 
Ligand Alternative name Function 
 
BMP2 
BMP3 
 
BMP2A 
Osteogenin 
 
Osteoinductive, osteoblast differentiation, apoptosis 
Most abundant BMP in bone, inhibits osteogenesis 
BMP3b GDF10  
BMP4 
BMP6 
BMP2 
Vgr1 
Osteoinductive, lung and eye development 
Osteoblast differentiation, chondrogenesis 
BMP7 OP1 Osteoinductive, development kidney and eye 
BMP8 OP2 Osteoinductive 
BMP9 GDF2 Hepatogenesis, development of nervous system 
BMP10  Cardiac development 
BMP11 GDF8, myostatin Patterning mesodermal and neuronal tissue 
BMP12 GDF7 Induces tendom-iliac tissue formation 
BMP13 GDF6 Induces tendon and ligament like tissue formation 
BMP14 GDF5 Chondrogenesis, enhances tendon healing, bone 
formation 
BMP15 GD9B Modifies follicle-stimulating hormone activity 
 
 
1.2.2 BMP receptors 
The BMP family members initiate their cellular actions by binding to 
transmembrane receptors with intrinsic serine/threonine kinase activity. This receptor 
family consists of type I and type II receptors, which are structurally similar (ten Dijke et 
al., 1996; Yamashita and Miyazono 1999; Massague and Chen 2000; Wrana 2000). 
Both types of receptors contain a small cysteine-rich extracellular ligand binding domain, 
a single hydrophobic transmembrane domain, and an intracellular segment containing 
the kinase domain. Type II receptors differ from type I receptors in that they lack a so-
called GS domain. The GS domain is a region located immediately upstream of the 
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kinase domain, and is rich in glycine and serine residues. It plays important roles in 
controlling type I receptor kinase function. Type II receptors have a constitutively active 
cytoplasmic kinase domain, but are unable to activate downstream signals in the 
absence of a type I receptor (Ventura et al., 1994; Wrana et al., 1994). 
The BMPs interact with three type II receptors, namely the BMP type II receptor 
(BMPRII) and activin type II receptors (ActRII and ActRIIB), and in turn activate four 
distinct type I receptors: BMPRIA (ALK3), BMPRIB (ALK6), ALK2 and ALK1 (Yamashita 
et al., 1996; Miyazono et al., 2005). 
The ligand-receptor relationship between various BMP ligands and their cognate 
receptors are not exclusive (see Table 1.2). Both ActRII and ActRIIB originally identified 
as activin receptors, can also act as receptors for BMP6, BMP7, and GDF5. In addition 
BMPRII can bind BMP2, BMP4, BMP6, BMP7, BMP15, GDF5, and GDF9. 
 
Table 1.2  The relationship between ligands, receptors (R), and Smads in the BMP 
family (after Shimasaki et al., 2004). 
 
Ligands Type II-R Type I-R Smads Refserences 
 
BMP2 
BMP4 
 
 
 
BMPRII 
 
 
ALK3 (BMPRIA) 
ALK6 (BMPRIB) 
 
 
Smad1/5/8 
 
(Liu et al., 1995) 
(Rosenzweig et al., 1995) 
 
 
GDF5 
 
BMPRII 
ActRII 
ActRIIB 
 
 
 
 
ALK3 (BMPRIA) 
ALK6 (BMPRIB) 
 
 
Smad1/5/8 
 
 
(Nishitoh et al., 1996) 
(Aoki et al., 2001) 
 
 
 
BMP6 
BMP7 
 
BMPRII 
ActRII 
ActRIIB 
 
 
 
 
ALK2 (ActRIA) 
ALK6 (BMPRIB) 
 
 
 
Smad1/5/8 
 
 
 
(Liu et al., 1995) 
(Ebisawa et al., 1999) 
 
 
BMP15 
 
 
BMPRII 
 
ALK6 (BMPRIB) 
 
Smad1/5/8 
 
(Moore et al., 2003) 
 
GDF9 
 
BMPRII 
 
Not identified 
 
Smad2 
 
(Vitt et al., 2002) 
 
 
After ligand binding, the constitutively active type II receptor forms a 
heterocomplex with the type I receptor and transphosphorylates the GS domain, which 
leads to the activation of the type I receptor-linked kinase. The activated type I receptor 
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transduces a signal by phosphorylation of downstream effector molecules. The 
assembly of the receptor complex is not only triggered by ligand binding, but is also 
stabilised by direct interaction between the cytoplasmic segments of the receptors. This 
model predicts that type II and type I receptors act in concert, which is supported by the 
findings that overexpression of the kinase-domain-truncated BMP type I receptors block 
the signal transduction induced by BMPs (Maeno et al., 1994; Suzuki et al., 1994; 
Namiki et al., 1997). In contrast, substitution mutations at the GS domain of BMP type I 
receptors activate downstream signalling in the absence of binding or phosphorylation 
by type II receptors (Wieser et al., 1995; Akiyama et al., 1997; Fujii et al., 1999). It 
remains unclear whether BMP ligands bind first to the type I, or to the type II receptor. 
The situation is complicated by the fact that BMPs bind with a low affinity to BMP type I 
or type II receptors individually, and with high affinity only when the two BMP receptor 
types are present together. With respect to ALK3, ALK6 and BMPRII, two models of 
receptor activation have been described. BMP binds with high affinity to ALK3 or ALK6 
and then recruits BMPRII into a hetero-oligomeric complex (BMP-induced signalling 
complexes: BISC). This process leads to activation of the p38 mitogen activated protein 
kinase (MAPK) pathway. The other alternative is to bind simultaneously to preformed 
hetero-oligomeric complexes consisting of at least one type I, and one type II receptor. 
This complex then activates the Smad signalling pathway. The stoichiometry of these 
receptor complexes remain to be elucidated (Nohe et al., 2002; Hassel et al., 2003).  
 
1.2.3 The BMP signalling pathways 
It is well established that ligand binding activates the type I receptor by 
phosphorylation, leading to signalling by a Smad restricted pathway (Heldin et al., 1997; 
Wrana 2000). Additionally, recent studies have demonstrated an involvement of the 
MAPK pathway in BMP signalling, mediated by TGFβ activated kinase 1 (TAK1)/ TAK1 
binding protein (TAB1) inducing the activation of p38. Several lines of evidence 
document the activation of the RAS pathway and extracellular signal-regulated kinase 
(ERK) pathway due to BMP stimulation, but little is known about this regulation at the 
molecular level (Figure 1.3) (Nohe et al., 2002). 
 
1.2.3.1 Smad-dependent pathways 
Smad proteins are known to function as key signal transducers downstream of 
the TGFβ superfamily type I receptors (Wrana and Attisano 2000). The activated BMP 
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type I receptor directly recruits and phosphorylates a set of cytoplasmic receptor-
regulated Smads (R-Smads), including Smad1, Smad5 and Smad8 which are known to 
preferentially transduce BMP signals. The phosphorylation of R-Smads at a carboxy 
terminal SSXS motif triggers the release of Smads from the receptor, and formation of 
homo and hetero-oligomers with Smad4 (also known as the Co-Smad), which is “shared” 
between several TGFβ signal transduction pathways (Kawabata et al., 1998; Mehra et 
al., 2000). The phosphorylation and heterocomplex formation then results in nuclear 
translocation, and after binding to DNA together with other transcription factors, 
regulation of the transcription of target genes (Miyazono et al., 2000; Souchelnytskyi et 
al., 2001; ten Dijke and Hill 2004). 
 
 
Figure 1.3  BMP receptor-signalling pathway. 
BMP can bind to the preformed oligomeric receptor complexes (PFC), which leads to the 
activation of the Smad signalling pathway. Binding of the ligand to the homo-oligomeric type I 
receptors recruitit of the type II receptor leads to the activation of the p38 pathway, possibly 
mediated by TGFβ activated kinase 1 (TAK1)/TAK1 binding protein (TAB1). Studies also show 
the activation of RAS and extracellular signal-regulated kinase (ERK) due to BMP stimulation, 
but not much is known about the molecular mechanism. BISC; BMP-induced signalling 
complexes (after Nohe et al., 2002). 
 
 
Structurally, R-Smads and Co-Smads are similar. They share two     
highly-conserved regions, an N-terminal MH1 (Mad Homology 1) domain and a     
C-terminal MH2 (Mad homology 2) domain, separated by a poorly-conserved linker 
region. However, the Co-Smad does not contain the C-terminal SSXS phosphorylation 
motif present in R-Smads, and is thus not phosphorylated by the receptor            
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(Macias-Silvia et al.1996; Zhan et al.1996). The MH1 domain of the Co-Smad and R-
Smads can bind to specific DNA sequences, while the MH2 domain mediates protein-
protein interaction with Smads, transcriptional coactivators like p300, CBP (histone 
acetylase), or co-repressors, resulting in the regulation of specific gene expression. 
 
The BMP signalling pathway is also negatively regulated. The BMP and activin 
membrane bound inhibitor (BAMBI), Smad ubiquitination regulatory factor-1 (Smurf1), 
Smad6 and Smad7 are the best known intracellular factors which are induced by BMP 
signalling and inhibit the BMP-Smad dependent pathway at different levels, establishing 
a negative feed-back loop. 
 
BAMBI. The BMP and activin membrane bound inhibitor (BAMBI) exhibits 
significant sequence similarity to TGFβ receptors, but lacks the intracellular kinase 
domain. It can function as a naturally occurring dominant-negative receptor which 
associates with other receptors and thus prevents formation of functional receptor 
complexes, and blocks BMP signalling (Onichtchouk et al., 1999; Sekiya et al., 2004). 
 
Smurf1. Smad-ubiquitination regulatory factor 1 (Smurf1) displays E3 ubiquitin 
ligase activity, interacts with Smad1 and Smad5, and specifically targets them for 
ubiquitination, leading to proteosomal degradation and thus signal inhibition      
(Murakami et al., 2003). 
 
Smad6 and Smad7. Unlike the other members of the Smad family, Smad6 and 
Smad7 are inhibitors of TGFβ superfamily signalling. Hence they are called inhibitory 
Smads (I-Smads). This inhibition occurs through their ability to complete with     
the R-Smads for binding to the activated type I receptors. Smad6 inhibits BMP signalling 
by forming a complex with Smad1, thereby competing with Smad4 binding                
(Hata et al., 1998; Miyazono et al., 2001). 
The BMP signalling can also be inhibited extracellularly by secreted proteins such as 
Chordin, Noggin, Gremlin, Dragon, Cerberus and Tolloid/BMP1-related metalloproteases 
(Yoshida et al., 2000; Gerlach-Bank et al., 2002). 
 
1.2.3.2 BMP-MAPK dependent pathway 
In addition to the canonical BMP-Smad-dependent signalling pathway the MAPK 
pathway also mediates TGFβ signal transduction. Activated BMP receptors may interact 
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with X-linked inhibitor of apoptosis (XIAP), which in turns activates the mitogen activated 
protein kinase kinase kinase (MAPKKK) TAK1 by interacting with TAB1. The TAK1 can 
activate nemo-like kinase (NLK) and inhibits the DNA-binding activity of the β-catenin/T-
cell-specific transcription factor (TCF) complex, which normally activates dorsally 
expressed target genes of the Wnt/β-catenin pathway (Iwasaki et al., 1999; Kimura et 
al., 2000). 
 
1.3 BMP signalling in lung development and homeostasis 
Different growth factors, including members of TGFβ superfamily such as BMPs, 
regulate diverse biological processes including migration, proliferation, and 
differentiation of pluripotent progenitor cells that are involved in the development of 
several organ systems during embryogenesis and in adult tissue repair. Regulation of 
these cellular functions is also critical for normal lung development and homeostasis 
(Kawabata et al., 1998; Sakou 1998). 
The BMPs play an essential role in the establishment of the basic embryonic 
body plan. Several studies in embryos have revealed that BMP4 induces ventral 
mesoderm formation. Gene targeting studies have demonstrated that BMP signals are 
required for gastrulation of mouse embryos. While BMP2 deletion-mutant embryos do 
form mesoderm cells, they fail to close the proamniotic canal, and also exhibit a defect in 
cardiac development. The majority of homozygous BMP4 null embryos die at or around 
the time of gastrulation, without forming embryonic mesoderm (Beppu et al., 2000; 
Warburton et al., 2003). 
Several BMPs, including BMP3, 4, 5 and 7, are expressed during embryonic lung 
development and exist in lung tissue throughout the adult life (Bellusci et al., 1996).The 
expression of BMP5 and BMP7 has been detected in the mesenchyme and the 
endoderm of the developing embryonic lung respectively, while BMP4 expression is 
restricted to the distal epithelial cells and the adjacent mesenchyme and plays an 
important role in regulating early branching morphogenesis. Addition of BMP4 to 
embryonic lung explant culture medium dramatically stimulates lung branching, whereas 
it inhibits the growth of isolated epithelial cells. Interestingly, in vivo overexpression of 
BMP4 (driven by the SP-C promoter in the distal endoderm of transgenic mice) causes 
abnormal lung morphogenesis, with cystic terminal sacs and inhibition of epithelial-cell 
proliferation. 
The BMPs act not only as instructive signals during embryogenesis but also contribute to 
the maintenance and repair of adult tissues. For example BMP7 inhibits      
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serum-stimulated and growth factor-induced proliferation of human aortic SMC       
(Dorai et al., 2000), while BMP2 has been shown to inhibit injury induced intimal 
hyperplasia in the rat carotid artery balloon injury model (Nakaoka et al., 1997). 
Most of the BMP signalling pathway components, such as BMP receptors (both 
type II and type I, ALK2, 3, and 6) and BMP-specific receptor-regulated Smads (R-
Smads) are expressed in early embryonic mouse lung development. These findings 
suggest strong involvement of this pathway in lung development and homeostasis. The 
SP-C promoter-driven overexpression of either the BMP antagonist Xnoggin or a 
dominant-negative ALK6 BMP receptor block BMP signalling, resulting in severely 
reduced distal epithelial cell phenotypes and increased proximal cell phenotypes in lungs 
of transgenic mice. The critical role of BMPRII and the BMP pathway in vascular 
development is evident from studies in knock-down mice. Homozygosity for the null 
mutation in the BMPR2 gene is lethal during early embryogenesis. Smooth muscle-
specific expression of a dominant-negative BMPRII in mice with activated expression 
after birth, develop increase pulmonary artery pressure, RV/LV+S ratio, and pulmonary 
arterial muscularisation with no increase in systemic arterial pressure (West et al., 2004). 
Gene targeting analyses have revealed the critical functions of Smad4 and Smad5, 
which act downstream of BMP receptors, during embryonic development. Smad4-/- 
embryos die before 7.5 days postcoitum (E7.5) with gastrulation defects and abnormal 
visceral endoderm formation. Smad5-/- embryos die between E9.5 and E11.5 and 
exhibit multiple defects including a lack of normal vasculature, as they fail to recruit 
vascular smooth muscle to endothelial structures (Warburton et al., 2003). 
 Taken together, these findings suggest that disruption of BMP signalling 
pathways may result in a failure of the crucial antiproliferative/differentiation mechanisms 
in the pulmonary vasculature and may couse vascular remodelling characteristics for 
PAH patients. To date, the most extensively studied molecule from this pathway remains 
BMPRII. Several mutations found in this receptor might cause disruption of BMP 
signalling that contribute to the cellular proliferation and vascular oblitreation observed in 
this disease. This hypothesis is supported by the finding that pulmonary arterial SMC 
(paSMC) described in patients with PAH exhibit altered growth responses to the BMPRII 
ligands compared with cells isolated from normal (control) lungs (Morrell et al., 2001). 
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1.4 BMPRII and pulmonary arterial hypertension 
1.4.1 Genomic structure and function of BMPRII 
The genomic structure of the BMPR2 gene, located on chromosome 2q33, 
covers approximately 190 kb, comprising 13 exons, which encode a 4 kb transcript that 
generates a polypeptide with 1038 amino acids in humans. The mature protein harbours 
four distinct functional domains, namely the extracellular ligand-binding domain encoded 
by exons 2 and 3, a single pass transmembrane domain generated by exon 4, and a 
serine/threonine kinase domain extending from exon 5 to exon 11. The sequence and 
structure of the receptor is highly conserved; for example, overall amino acid sequence 
identity between mouse and human BMPRII is 96.6% (Beppu et al., 1997). Unique to 
BMPRII among the members of TGFβ receptor superfamily is the large C-terminal 
cytoplasmic tail encoded by exons 12 and 13. The precise function of this domain 
remains unknown (Rosenzweig et al., 1995). To date, three molecules that interact with 
this region of BMPRII have been identified: LIM kinase 1 (LIMK1), Tctex1 and Src 
kinase. The LIMK1 regulates dynamics of the cytoskeletal protein actin by 
phosphorylation and inactivation of cofilin. The BMPRII inhibits the ability of LIMK1 to 
phosphorylate cofilin through interaction with its C-terminal tail, and this inhibition is 
alleviated by BMP4 (Foletta et al., 2004). The Tctex1 protein is the light chain of the 
motor complex dynein. The BMPRII induces phosphorylation of Tctex, resulting in the 
movement of Tctex along the microtubules and the efficient activation of downstream 
signal mediators (Machado et al., 2003). The interaction between BMPRII and c-Src 
tyrosine kinase inhibit c-Src tyrosine kinase activity in the presence of BMP ligand by 
reducing its phosphorylation at tyrosine-418 residue. The inhibition of c-Src activity by 
BMP signaling may inhibit downstream cell cycle regulators such as cyclins D and E and 
subsequently prevent smooth muscle cell proliferation (Wong et al., 2005). In addition, 
Hassel et al., 2000 performed a proteomics analysis of BMPRII interacting proteins and 
found that several proteins of the cytoskeletal components interact with the C-terminal 
tail as well as the kinase domain of BMPRII. Thus, the C-terminal tail is thought to 
posses important regulatory functions for cytoskeletal proteins. Interestingly, an isoform 
of BMPRII termed the BMPRII “short-form” is generated by alternative splicing of exon 
12 and the exposure of a premature translation termination codon within exon 13, and 
thus lacking the long cytoplasmic domain, was recently identified. Overexpression of the 
short form of BMPRII indicates that it is capable of activating Smads, indicating that the 
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cytoplasmatic tail might not be required for the well-characterised BMP signalling 
pathway. 
The BMPRII is widely expressed in different tissues, including heart, brain, 
skeletal muscle, kidney and lung. In normal lungs, BMPRII mRNA and protein are 
predominantly found in endothelial cells, macrophages, and to a lesser extent SMC 
(Atkinson et al., 2002).  
 
1.4.2 BMPR2 mutations in pulmonary arterial hypertension patients 
Extensive analyses of the BMPR2 coding region and intron-exon boundaries 
have been conducted in patients with FPAH and IPAH from a wide range of ethnic 
groups, including Americans, Europeans, Asians (Deng et al., 2000; Machado et al., 
2001; Morrell et al., 2001; Newman et al., 2001; Thomson et al., 2001; Nishihara et al., 
2002; Rudarakanchana et al., 2002; Uehara et al., 2002; Morisaki et al., 2004; Sugiyama 
et al., 2004). Germline mutations (therefore present in all cell types) were detected in 
55% (40 to 73) of recognised familial cases. In IPAH, the mutation rate ranges from 11% 
to 40%. These findings indicate that this autosomal dominant disorder displays reduced 
penetrance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4  Alignment of described BMPR2 mutations. 
The BMPR2 gene structure is aligned with its corresponding cDNA, along with the mutations 
described thus far. BMPRII protein domains are designated by different intensities of grey color. 
SP; signalling peptide, TM; transmembrane domain (after Eickelberg and Seeger, 2005). 
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To date, more than 100 different mutations have been described in both familial 
and sporadic cases (see Table 5.1, Appendix). These span the entire open reading 
frame of the BMPR2 gene. Among the known mutations, at least four different types of 
mutations have been identified (Machado et al., 2001). In the first group, nonsense or 
frame-shift mutations in the extracellular domain lead to a premature truncation of the 
proteins and absence of BMPRII protein on the plasma membrane. The second group is 
characterised by missense mutations in the extracellular domain, mostly involving highly 
conserved cysteine residues. The third group of mutations has either missense or frame- 
shift mutations in the kinase domain, while the fourth group has frame-shift or nonsense 
mutations within the cytoplasmic tail, resulting in cytoplasmic truncation of the receptor 
protein (see Figure 1.4). 
 
1.4.3 Functional consequences of BMPR2 mutations 
The different types of mutations distributed throughout the entire coding region of 
the BMPR2 gene suggest a high degree of heterogeneity concerning their contribution to 
the pathogenesis of PAH. The possible consequence of mutations occurring in 
conserved or functionally critical domains of the receptor may interfere with BMP 
signalling and might reduce or completely abolish the signal-transducing abilities of the 
receptor. The mechanism by which BMPR2 mutations disrupt BMP/Smad signalling is 
heterogeneous and mutations can result in alterations to transcriptional activity, 
decreased ligand binding ability, or improper BMPRII trafficking to the membrane 
(Eddahibi et al., 2002; Rudarakanchana et al., 2002). 
 
1.4.3.1 Loss of transcriptional activitiy 
Experiments investigating disease associated with BMPR2 mutations suggest a 
dominant-inhibitory effect of mutations in the extracellular or kinase domains on receptor 
function, with respect to Smad signalling. Receptors with mutations in these two 
domains are neither able to induced transcriptional activation of a BMP-specific promoter 
reporter construct nor are they able to phosphorylate BMP-specific Smads.     
Co-expression with wild-type BMPRII represses, in a dose-dependent manner, the 
transcriptional activity induced by this receptor. In contrast, mutations in the C-terminal 
tail of the receptor do not affect its biological activities. In agreement with these findings, 
these receptors are able to phosphorylate BMP-specific Smads, albeit less efficiently 
than the wild-type BMPRII (Rudarakanchana et al., 2002). 
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1.4.3.2 Decreased ligand binding ability 
Different mutations were also tested for their ligand-binding ability. Structural 
changes to the extracellular domain of the receptor can abolish ligand-binding capacity, 
while BMPRII variants generated from a BMPR2 gene carrying a mutation in the kinase, 
or C-terminal encoding domain in the presence of ALK3 bound BMP6 and BMP4 
efficiently (Rudarakanchana et al., 2002). 
 
1.4.3.3 Failure of BMPRII trafficking to the plasma membrane 
In PAH patients, many of the missense mutations within the extracellular domain-
encoding region of BMPRII have been found in cysteine codons (Machado et al., 2001). 
It is known that extracellular cysteine residues of BMPRII are essential for the formation 
of the correct three-dimensional structure required for membrane targeting of many 
receptors (Zeng et al., 1999). Overexpression of a mutated gene encoding BMPRII 
carrying cysteine substitutions in the ligand-binding domain or kinase domain, resulted in 
altered receptor trafficking to the cell surface, and most of the abnormal proteins were 
detected in the endoplasmic reticulum. In contrast, receptors carrying non-cysteine 
variants within the kinase domain do reach the cell surface but fail to activate a BMP 
Smad-responsive luciferase reporter gene. These results suggest that loss of signal-
transducing abilities induced by the missense mutations in exons encoding the 
extracellular ligand binding region are not only due to loss of ligand-binding ability of the 
extracellular domain, but are also caused by subcellular miss-localisation 
(Rudarakanchana et al., 2002). 
 
1.4.3.4 Activation of Smad-independent BMP signalling pathways 
Overexpression of mutated BMPR2 genes leads to ligand-independent activation 
of p38 MAPK and enhanced serum-induced proliferation of mouse epithelial cells. Based 
on the results of these studies, a reduced cell-surface expression of BMPRII might favor 
activation of p38 MAPK-dependent signalling pathway, while inhibiting Smad-dependent 
signalling in a mutation-specific manner. Ligand-induced and ligand-independent 
signalling may be an important mechanism contributing to the abnormal cell proliferation 
observed after transfection with expression constructs carrying mutations in the BMPR2 
gene (Rudarakanchana et al., 2002). 
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1.4.3.5 Increased of BMP signalling 
Based on recent studies demonstrating that ablation of BMPRII in paSMC 
does not abolish BMP signalling but leads to diminished signalling by BMP2 and 
BMP4 and augmented signalling by BMP6 and BMP7, there are two novel 
hypotheses which might explain the pathological consequences of BMPR2 mutations. 
It is possible that a truncated form of BMPRII lacking a transmembrane domain, 
kinase and C-terminal tail might increase BMP signalling by providing inactive targets 
for constitutively expressed inhibitors. Another explanation for these observations is 
that BMPRII might function not only by transducing BMP signals, but also by 
regulating the activity of alternative receptors such as ActRIIa. Disruption of BMPRII 
in paSMC force BMP signals to be transduced by an alternate receptor, ActRIIa, a 
function that appears to be suppressed by BMPR2 in wil-type cells (Yu et al., 2005). 
 
1.4.3.6 Down-regulation of BMPRII expression 
The expression of BMPRII protein in the lung is dramatically reduced in patients 
harboring an underlying BMPR2 mutation that predicted to cause truncation of the 
protein. In addition, BMPR2 expression is markedly reduced in subjects, where no 
BMPRII mutation was identified (Atkinson et al., 2002). These findings stress the 
importance of understanding how other environmental and genetic factors might regulate 
the expression of BMPRII in lung cells, and might provide important clues as to why the 
vascular abnormality is restricted to the lung, particularly since BMPRII is widely 
expressed in normal adult tissues. 
 
1.4.3.7 Failure of antiproliferative effects on vascular cells 
It is well documented that BMP2, 4 and 7 display a significant antiproliferative 
effect on normal paSMC. Interestingly, this growth-inhibitory effect is diminished in cells 
obtained from patients with IPAH or FPAH. This phenomenon was observed in all cases, 
irrespective of whether or not specific BMPR2 mutations were identified, suggesting the 
defective BMP-mediated signalling may be a common factor in IPAH and FPAH 
(Robbins 2004). 
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1.5 Experimental design and aim of the project 
Heterozygous mutations in the BMPR2 gene, encoding the type II BMP receptor, 
which have been identified in PAH patients suggest that alterations to BMPRII function 
may be involved in the onset and/or progression of PAH. To further elucidate the 
function of BMPRII in this context, we sought to:  
 
- Identifiy novel interacting partners of BMPRII by yeast two-hybrid analysis, 
using the kinase domain and total intracellular part of the receptor as a bait. 
 
- Verify true positives - thus real interacting partners of BMPRII by further in vitro 
(GST pull down), and in vivo (co-immunoprecipitation, co-localisation in tissue 
and specific cell types) studies. 
 
- Demonstrate the relevance of these interactions in lung homeostasis and their 
influence on the pathogenesis of PAH by functional analyses. 
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2 Materials and methods 
2.1 Materials 
2.1.1  Equipment 
Cell Culture Incubator; Cytoperm2     Heraeus, Germany 
Chroma SPIN-1000 DEPC-H2O Columns   Biosciences, Clontech, USA 
Developing machine; X Omat 2000     Kodak; USA 
Electrophoresis chambers      Bio-Rad, USA 
Fluorescence microscope; LEICA AS MDW   Leica, Germany 
Freezer -20 °C      Bosch, Germany 
Freezer -40 °C      Kryotec, Germany 
Freezer -80 °C      Heraeus, Germany 
Fridge +4 °C       Bosch, Germany 
Mini spin centrifuge       Eppendorf, Germany 
Multifuge centrifuge, 3 s-R      Heraeus, Germany 
Light microscope; LEICA DMIL     Leica, Germany 
PCR-thermocycler       MJ Research, USA 
Pipetboy        Eppendorf, Germany 
Pipetmans: P10, P20, P100, P200, P1000    Gilson, France 
Power Supply; Power PAC 300     Bio-Rad, USA 
Western Blot Chambers: Mini Trans-Blot   Bio-Rad, USA 
Mini-Protean 3 Cell   Bio-Rad, USA 
Vortex machine       Eppendorf, Germany 
Film cassette       Sigma-Aldrich, Germany 
Filter Tip FT: 10, 20, 100, 200, 1000    Greiner Bio-One, Germany 
Filter units 0.22 µm syringe-driven     Millipore, USA 
Glass bottles: 250, 500, 1000 ml     Fisher, Germany 
Gel bloting paper 70 × 100 mm     Bioscience, Germany 
Petri dish with vents       Greiner Bio-One, Germany 
Pipette tip: 200, 1000 µl,      Sarstedt, Germany 
Pipette tip 10 µl       Gilson, USA 
Radiographic film X-Omat LS     Sigma-Aldrich, Germany 
Serological pipette: 5, 10, 25, 50 ml    Falcon, USA 
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Test tubes: 15, 50 ml      Greiner Bio-One, Germany 
Tissue culture chamber slides     BD Falcon, USA 
Tissue culture dish 100 mm      Greiner Bio-One, Germany 
Tissue culture flask 250 ml      Greiner Bio-One, Germany 
Tissue culture plates: 6, 24, 48 well    Greiner Bio-One, Germany 
Trans blot transfer medium (0.2 µm)    Bio-Rad, USA 
 
2.1.2 Reagents 
Acetic acid        Merck, Germany 
Acrylamide solution, Rotiphorese Gel 30   Roth, Germany 
Agarose        Invitrogen, UK 
Ammonium persulfate (APS)     Promega, Germany 
Ammonium sulfate       Sigma-Aldrich, Germany  
Ampicillin sodium       Sigma-Aldrich, Germany 
β-glycerophosphate      Sigma-Aldrich, Germany 
β-mercaptoethanol       Sigma-Aldrich, Germany 
Bromophenol blue       Sigma-Aldrich, Germany 
Calcium chloride       Sigma-Aldrich, Germany 
3-[3-chloramidopropyl) dimethylammonio]- 
1-propanesulfonate (CHAPS)    Sigma-Aldrich, Germany 
D-(+)-Glucose       Sigma-Aldrich, Germany 
D-MEM medium       Gibco BRL, Germany 
RPMI/640 medium       Gibco BRL, Germany 
Difco yeast nitrogen base without amino acids   Biosciences, Clontech, USA 
Dimethyl sulfoxide (DMSO)      Sigma-Aldrich, Germany 
Ethylendinitrilo-N, N, N´, N´, -tetra-acetic acid (EDTA)  Promega, USA 
Dublecco’ s phosphate buffered saline 10 × (PBS) Laboratories, Austria 
Ethanol absolute       Riedel-de Haen, Germany 
Foetal bovine serum (FBS)      Gibco BRL, Germany 
Gel extraction kit      Qiagen, Germany  
Glass beads        Sigma-Aldrich, Germany 
Glycine       Roth, Germany 
Glycerol        Merck, Germany 
2-(-4-2-hydroxyethyl)-piperazinyl-1-ethansulfonate  
(HEPES)       Sigma-Aldrich, Germany 
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Histostain-SP Kit      Zymed, USA 
Igepal CA-630       Sigma-Aldrich, Germany 
Lipofectamine       Invitrogene, UK 
Lithium acetate       Sigma-Aldrich, Germany 
Luria-Bertani Medium       Invitrogen, UK 
MiniElute Gel Extraction Kit      Qiagen, Germany 
Magnesium chloride       Sigma-Aldrich, Germany 
Magnesium sulfate       Sigma-Aldrich, Germany 
Methanol        Fluka, Germany 
pGEM-T Easy Vector System Kit    Promega, Germany 
Platinum Taq DNA polymerase    Invitrogen, Germany 
Polyethylene glycol 6000      Merck, Germany 
Potassium acetate       Sigma-Aldrich, Germany 
Potassium chloride       Merck, Germany 
Potassium phosphate      Sigma-Aldrich, Germany 
Precision Plus ProteinTM Standards     Bio-Rad, USA 
2-Propanol        Merck, Germany 
Pure Yield Plasmid Midiprep System   Promega, Germany 
Restriction endonucleases     Promega, Germany 
RNase inhibitor      Promega, Germany 
RNeasy Midi Kit      Qiagen, Germany 
Rnase H reverse transcriptase    Promega, Germany 
SD/-Ade supplenent       BD, Clontech, USA 
SD/-His supplenent       BD, Clontech, USA 
SD/-Leu/-Trp supplement      BD, Clontech, USA 
SD/-Ade/-His/-Leu/-Trp supplement     BD, Clontech, USA 
Select agar        Invitrogen, UK 
Select peptone 140       Gibco BRL, Germany 
Select yeast extract       Gibco BRL, Germany 
Sodium acetate       Sigma-Aldrich, Germany 
Sodium chloride       Merck, Germany 
Sodium dodecyl sulfate (SDS)     Promega, USA 
Sodium phosphate       Sigma-Aldrich, Germany 
Sodium sulfate       Merck, Germany 
Taq DNA polymerase      Invitrogen, Germany 
T4 DNA ligase       Promega, Germany 
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Tween 20        Sigma-Aldrich, Germany 
Tris         Roth, Germany 
Triton X-100        Promega, USA 
Trypsin/EDTA       Gibco BRL, Germany 
QIAprep Spin Miniprep Kit     Qiagen, Germany 
Yeast Plasmid Isloation Kit     Clontech, USA 
 
2.1.3 Cell Lines 
2.1.3.1 Mammalian cell lines 
NIH/3T3 (Swiss mouse embryo), fibroblast   DSMZ, Germany 
COS 7 (African green monkey kidney) fibroblast-like DSMZ, Germany 
A549 (human lung carcinoma), epithelial   DSMZ, Germany 
 
2.1.3.2 Yeast cells 
Sacharomyces cerevisiae AH109    Clontech, USA 
Sacharomyces cerevisiae Y187    Clontech, USA 
 
2.1.3.3 Prokaryotic cells 
E. coli strains: 
DH5α         Clontech, USA  
BL21        Clontech, USA  
KC8        Clontech, USA 
 
2.1.4 Animals 
2.1.4.1 A monocrotaline rat model of pulmonary arterial hypertension 
Monocrotaline (MCT) was dissolved in 0.5 M HCl, and the pH was adjusted to 7.4 
with 0.5 M NaOH. The solution was administered as a single intrajugular injection   
(60 mg/kg) to male Sprague-Dawley rats. Control rats received an equal volume of 
isotonic saline. Pathological changes were observed after one to five weeks after 
treatment. Right ventricular hypertrophy was used as a marker for PAH development. 
Right ventricular hypertrophy was quantified as a factor for PAH changes. The heart was 
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dissected, and the ratio of the right ventricle to left ventricle plus septum weight  
(RV/LV + S) was used as an index of right ventricular hypertrophy. 
 
2.1.4.2 Hypoxia mouse model of pulmonary arterial hypertension 
Male BALB/cAnNCrlBR mice (20 to 22 g; Charles River, Sulzfeld, Germany) were 
exposed to normobaric hypoxia [inspiratory O2 fraction (FiO2) 0.10] in a ventilated 
chamber. The level of hypoxia was held constant by an autoregulatory control unit 
supplying either nitrogen or oxygen. Excess humidity in the recirculating system was 
prevented by condensation in a cooling system. The CO2 was continuously removed by 
soda lime. Mice exposed to normobaric normoxia were kept in a similar chamber at a 
FiO2 of 0.21. After 1, 7 or 21 days, the animals were anesthetised by intraperitoreal 
administration of 180 mg of sodium pentabarbital/kg body weight. A cannula was 
inserted into the trachea by tracheostomy, a midline thoracotomy was performed, and 
the lungs were flushed via a catheter in the pulmonary artery with Krebs-Henseleit buffer 
(4.3 mM KCl, 1.1 mM KH2PO4, 2.4 mM CaCl2 1.3 mM MgCl2, and 13.32 mM glucose) at 
pressure of 20 cm H2O at room temperature. It was equilibrated with a gas mixture 1% 
O2, 5.3% CO2, balanced with N2. The pH was adjusted with NaHCO3 to 7.40. During 
perfusion of the lung, the buffer was allowed to drain freely from a catheter in the left 
ventricle. Once the effluent was clear of blood, lungs were dissected and immediately 
frozen in liquid nitrogen. Preparation of the hypoxic animals was continuously performed 
in the hypoxic environment. As a factor for PAH changes, the heart was dissected, and 
RV/LV + S ratio was calculated as an index of right ventricular hypertrophy. 
 
2.2 Methods 
2.2.1 RNA isolation 
RNA isolation from lung tissue or cell lines was performed according to the 
manufacturer’s instructions provided together with the reagents in the RNeasy Midi Kit. 
 
2.2.2 Reverse Transcription 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) is an enzymatic 
reaction carried out by reverse transcriptase (RT), which synthesises cDNA using RNA 
as a template. 
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To perform RT reactions, 100 to 500 ng of total mouse or human RNA was mixed 
with 4 µl of oligo-(dT)15 (100 µg/ml) primers in a PCR tube. Samples were heated at     
70 °C for 5 min, chilled on ice, and the following RT reaction components were added.  
 
2.2.2.1 RT - Mix  
Components:    Volume:  Final concentration: 
5 × RT buffer (MgCl2 free)  4 µl   1 × 
25 mM MgCl2    4.8 µl   6 mM  
10 mM dNTP mix   1 µl   0.5 mM 
RNAsin inhibitor (1 U/µl)  1 µl   1.0 U 
Reverse Transcriptase (1 U/µl) 1 µl   1.0 U 
RNAse free water   to 20 µl  not applicable 
 
The RT amplification was performed as follows: 25 °C (5 min), 42 °C (1 h). 
Newly generated cDNA was used for PCR amplification immediately, or stored at -20 °C.  
 
2.2.3 The Polymerase Chain Reaction (PCR) 
The Polymerase Chain Reaction (PCR) is a method, which allows million-fold 
amplification of DNA segments from selected regions of the genome. The newly 
synthesised DNA is produced in a reaction catalyzed in vitro by purified DNA 
polymerase. 
The reaction consists of three steps: denaturation (generation of single strand DNA), 
annealing (binding of primers to the target sequence), and extension (amplification of  
a sequence of interest by polymerase enzyme). 
 
2.2.3.1 PCR - Mix  
The following components were combined in a 0.5 ml microcentrifuge tube, on ice: 
 
Components:     Volume:  Final concentration:  
10 × PCR buffer (MgCl2 free)   5 µl   1 × 
10 mM dNTP mixture    1 µl   0.2 mM each 
50 mM MgCl2     1.5 µl   1.5 mM 
10 µM forward primer    1 µl   0.2 µM 
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10 µM reverse primer    1 µl   0.2 µM 
Template DNA    ~1 µl   ** 
Platinum Taq DNA Polymerase (5 U/µl) 0.2 µl   1.0 U 
Autoclaved, deionised water   to 50 µl  not applicable 
 
**1 µg mammalian genomic DNA or 1.0 to 100.0 pg of plasmid DNA 
All primers sequences used for PCR amplification are shown in Table 5.2, Appendix. 
 
The components were mixed briefly. After denaturing at 94 °C for 5 min, the PCR 
amplification was performed. 
 
2.2.3.2 PCR program 
To perform effective DNA amplification 20-35 cycles of PCR reaction were 
required. 
Time and temperature for particular steps were performed as follows: 
 
Denaturation  30 s   94 °C 
Annealing  30 s   55 °C  (GC content <50%) or 
     60 °C (GC content >50%)  
Extension*  ~60 s/kb product 72 °C 
 
* The PCR was completed by incubation 10 min at 72 °C 
New generated DNA of interest was immediately used for cloning or stored at -20 °C. 
 
2.2.4 Site-directed mutagenesis 
The QuikChangeTM site-directed mutagenesis strategy was employed to 
introduce mutation into cDNAs. The QuikChangeTM mutagenesis was performed using 
Pfu DNA polymerase, a proofreading thermostable DNA polymerase with high fidelity. In 
the reaction, double-stranded pGEX-4T1 plasmid containing cDNA insert endcoding the 
kinase domain of BMPR2 served as a template, and a pair of synthesised 
complementary oligonucleotides as primers. The primers contained the desired mutation 
in the middle, flanked by 10-15 deoxynucleotides bases of 100% sequence at wild-types 
end. During thermocycling, the primers annealed to the complementary strands of the 
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template and were extended by Pfu DNA polymerase. On incorporation of the 
oligonucleotide primers, a mutated plasmid containing staggered nicks was generated. 
 
2.2.4.1 The QuikChangeTM PCR-Mix  
Components:     Volume:  Final concentration:  
10 × Pfu polymerase buffer    5 µl   1 × 
10 mM dNTP mixture    1 µl   0.2 mM each 
10 µM forward primer    1 µl   0.2 µM 
10 µM reverse primer    1 µl   0.2 µM 
Template DNA    ~1 µl   ~ 50 ng 
Pfu DNA Polymerase (6 U/µl)  0.5 µl   3.0 U 
Autoclaved, deionised water   to 50 µl  not applicable 
 
Between 30-35 temperature cycles were performed. The cycling parameters were 
identical to those used for normal PCR amplification (see 2.2.3.2), exept that the 
extension time was 2 min/kb of plasmid length. Primers sequences for this reaction are 
presented in Table 5.3, Appendix. 
 
Following the QuikChangeTM reaction, the product was treated with 20 U DpnI for 1 h, at 
37 °C. The DpnI endonuclease is specific for methylated and hemimethylated DNA, and 
was therefore used to digest the parental DNA template and to select the mutated-
daughter DNA strand. An aliquot of the nicked DNA plasmid incorporating the desired 
mutation was transformed into E. coli DH5α, where the nicks were repaired. The plasmid 
was expended, purified and fully sequenced to ensure presence of the expected 
mutations. 
 
2.2.5 Gel electrophoresis  
Gel electrophoresis is a method that allows separation of macromolecules, either 
nucleic acids or proteins, based on size, electric charge, pH and other physical 
properties. 
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2.2.5.1 Agarose gel electrophoresis 
To analyse or separate nucleic acid fragments, agarose gel electrophoresis was 
performed according to a standard protocol (Sambrook et al., 1989). Depending on the 
size of DNA fragments to be separated, 1-2% agarose gels containing 0.5 µg/ml 
ethidium bromide, a fluorescent intercalating dye, were prepared in 1 × Tris-acetate-
EDTA (TAE) buffer. Different gels, varying in agarose content, were used to resolved 
DNA fragment of different sizes: 
 
Agarose concentration (%):  DNA length (bp): 
1.0         400-8000 
1.2         300-7000 
1.5         200-4000 
2.0         100-3000 
 
Before loading onto the gel, nucleic acid samples were mixed 1:5 with 6 × agarose  
gel-loading buffer. The electrophoresis was performed at 100 V/cm, in 1 × TAE buffer. 
For analytical gels, the electrophoresis result was illuminated with short wavelength 
ultraviolet light (λ = 254 nm), and photographed. 
 
1 × TAE buffer: 
40 mM Tris-acetate, pH 8.0 
1 mM EDTA; pH 8.0 
 
6 × agarose gel-loading buffer: 
0.025% (w/v) bromophenol blue 
40% (w/v) sucrose 
 
2.2.5.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
For the analytical separation of proteins under SDS-denaturating conditions, gels 
were composed of an 8-15% separating gel and a 6% stacking gel (~2 cm long). Before 
loading, proteins samples were mixed with an equal volume of 2 × SDS gel-loading 
buffer, and denaturated by heating for 5 min at 95 °C. The electrophoresis was 
performed with a vertical gel chamber in 1 × SDS-running buffer. 
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Stacking gel: 
5% acrylamide/bisacrylamide 
125 mM Tris-HCl, pH 6.8 
0.1% (w/v) SDS 
0.1% (w/v) APS 
0.1% (v/v) TEMED 
 
Separating gel: 
8-12% acrylamide/bisacrylamide 
375 mM Tris-HCl, pH 8.8 
0.1% (w/v) SDS 
0.1% (w/v) APS 
0.1% (v/v) TEMED 
 
1 × SDS-running buffer: 
25 mM Tris-HCl, pH 8.3 
250 mM glycine 
0.1% (w/v) SDS 
 
2 × SDS gel-loading buffer: 
125 mM Tris-HCl, pH 6.8 
20% (v/v) glycerol 
4% (w/v) SDS 
10% (v/v)  β-mercaptoethanol 
0.025% (w/v) bromophenol blue 
 
2.2.6 Recombinant DNA technology 
Cloning involves the use of recombinant DNA technology to propagate DNA 
fragments inside a foreign host. The fragments are amplified in a PCR reaction or are 
isolated from chromosomes using restriction enzymes and then united with a carrier  
(a vector, a small, self-replicating circular molecule of DNA that is separate from the 
chromosomes). Following introduction into suitable host cells, the DNA fragments can 
then be reproduced along with the host cell DNA.  
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2.2.6.1 PCR product purification 
To clone a gene of interest into an expression vector, the DNA of interest was 
first amplified by PCR (see 2.2.3), and separated on the agarose gel. Bands of the 
expected size were excised and gel-purified using a commercially available Gel 
Extraction Kit.  
 
2.2.6.2 Ligation of PCR products into the pGEM-T Easy Vector 
Purified PCR product was ligated into the pGEM-T Easy vector containing a 
complementary unpaired 3´-thymidine residue that was complementary to the single 
3´-adenosine overhang generated by Taq DNA polymerase. The reaction was carried 
out with bacteriophage T4 DNA ligase overnight at 16 °C using the pGEM-T Easy Vector 
System Kit. 
 
2.2.6.3 Ligation-Mix 
Components:     Volume: 
2 × rapid ligation buffer   5 µl 
pGEM-T Easy Vector (50 ng)  1 µl 
Purified PCR product     x µl* 
T4 DNA ligase    1 µl 
Autoclaved, deionised water   to 10 µl 
 
*dependent on the DNA concentration  
 
2.2.7 Subcloning into expression vectors 
To clone DNA of interest into an expression vector, the DNA fragment containing 
the gene of interest was isolated from the pGEM-T Easy vector using restriction 
enzymes and then ligated into a plasmid that had been cut with the same restriction 
enzymes, to generate complementary ends (“sticky end”). Vectors and restriction sites 
used for cloning of particular genes are ilustrated in Table 5.5, Appendix. 
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2.2.7.1 DNA digestion using restriction endonucleases 
The digestion reaction was carried out by appropriate restriction endonucleases, 
which recognise short DNA sequences and cut the DNA molecules at those specific 
sites. Digestion was performed at 37 °C for 1 h. 
 
Restriction reaction mix contained: 
Components:      Amount: 
10 × restriction endonuclease buffers  2 µl 
Restriction endonuclease    1 to 5 U/µg DNA 
DNA sample in H2O or Tris/EDTA (TE) buffer 0.1 to 4 µg  
Autoclaved, deionised water    up to 20 µl 
The following restriction endonucleases were employed in this study: 
 
Enzymes:   Recognition and cleavage site: 
AluI     AG↓CT 
BamHI    G↓GATCC 
EcoRI     G↓AATTC 
EcoRV    GAT↓ATC 
HindIII     A↓AGCTT 
XhoI     C↓TCGAG 
 
After digestion the insert and vector were separated by agarose gel electrophoresis, 
extracted and ligated over night, and the ligation mixture was transformed into 
competent E. coli DH5α cells. After minipreparation, to screen for the presence of an 
insert of the correct size plasmids were digested with appropriate restriction enzymes. 
In-frame cloning was verified by sequencing. 
 
2.2.8 Immunological methods 
2.2.8.1 Immunoblot (Western blot) 
2.2.8.1.1 Protein extraction from mammalian cells 
Confluent monolayers of mammalian cells were washed twice with ice-cold 
Dublecco’s phosphate-buffered saline (PBS), after which lysis buffer was applied directly 
to cell monolayers (100 µl/100 mm2), and cells were detached by scraping, transferred 
Materials and methods        32 
 
into 1.5 ml microfuge tubes, incubated on ice for 30 min for complete lysis, and 
centrifuged for 15 min at 13 000 g. After centrifugation, the supernatant was mixed with 
2 × SDS gel-loading buffer, boiled, and resolved by SDS-PAGE. 
 
2.2.8.1.2 Protein extraction from yeast cells 
Total protein extracts from a 50 ml liquid culture of S. cerevisiae AH109 
transformed with bait constructs were prepared by boiling pellets of yeast cells grown to 
an OD600 of 0.6 in limiting synthetic medium lacking tryptophan in 50 µl of sample buffer. 
 
Sample buffer: 
60 mM Tris-HCl, pH 6.8 
10% (v/v) glycerol 
2% (w/v) SDS 
5% (v/v) β-mercaptoethanol 
0.025% (w/v) bromophenol blue. 
 
2.2.8.1.3 Protein bloting 
Proteins resolved by SDS-PAGE were transferred to a 0.25 µm pure 
nitrocellulose membrane. Transfer was performed at 120 V for 1 h. 
 
2.2.8.1.4 Protein detection 
For protein detection, membranes were blocked for 1 h in blocking buffer and 
then incubated overnight at 4 °C with the appropriate primary antibody in blocking buffer. 
After three washes for 10 min with Tris-buffered saline containing 0.1% (v/v) Tween 20 
(TBST), the membranes were incubated for 1 h with horseradish-peroxidase-labelled 
secondary antibody, and washed again 5 × for 10 min with the same buffer. Detection of 
protein was performed using the enhanced chemiluminescent immunoblotting system 
and exposure to radiographic film. Antibodies are listed in Table 5.6, Appendix. 
 
Transfer buffer, pH 7.4: 
24 mM Tris base  
193 mM glycine  
10% (v/v) methanol 
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Blocking buffer:  
5% (w/v) non-fat dry milk in PBS, containing 0.01% (v/v) Tween 20 
 
TBS buffer: 
20 mM Tris, pH7.4 
15 mM NaCl 
 
TBST buffer: 
20 mM Tris, pH7.4 
15 mM NaCl 
0.05% (m/v) Tween 20 
 
2.2.8.2 Co-immunoprecipitation 
This method for identification of protein-protein interaction was used to verify 
whether two proteins of interest identified by yeast two-hybrid screen associated in 
mammalian cells. 
Either NIH/3T3 or COS 7 cells were co-transfected with HA-BMPRII and Myc-
RACK1 expression vectors using LipofectamineTM 2000. After 48 h cells were washed 
twice with ice-cold PBS and lysed using buffer for immunoprecipitation (IP buffer) 
containing  0.5% (v/v) Triton X-100 or NP-40, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
10 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 100 mM NaF and a 
protease inhibitor cocktail. Proteins were solubilised on ice for 30 min. Cell lysates were 
clarified by centrifuging at 13 000 g for 15 min. To remove proteins that non-specifically 
bind to the protein A-Sepharose beads cell lysate were incubated for 30 min at 4 °C with 
50 µl of protein A-Sepharose on a rotating shaker. Pre-cleared lysate was incubated with 
gentle shaking at 4 °C for 2 h with anti-HA monoclonal antibody cross-linked to protein    
A-Sepharose beads. Immunocomplexes were washed three times with IP buffer, 
dissociated by boiling in SDS gel-loading buffer and resolved by SDS-PAGE, transferred 
to nitrocellulose and immunobloted for Myc-RACK1 with an mouse monoclonal anti-Myc 
antibody as described in Section 2.2.8.1. 
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2.2.8.3 Glutathione S-transferase (GST) pull-down  
This method for the identification of associated proteins was used to verify the 
interactions between a GST-fusion protein and a protein of interest in a mammalian cell 
lysate.  
BMPRII fused to GST was overexpresed in E. coli BL21. Expression was induced by 
adding IPTG to a final concentration of 1 mM to a bacterial culture at OD600~0.5. Bacteria 
were cultured for 4 h at 27 °C with shaking at 120 rpm, and centrifuged at 5 500 g for  
20 min. The pellet was resuspended in Lysis Buffer B1 and sonicated. After complete 
lysis, the lysate was centrifuged at 15 000 g and the supernatant was applied to a 
gluthatione-Sepharose matrix and incubated for 2 h at 4 °C with rotation. To avoid non-
specific binding, beads were extensively washed with Washing Buffer B2 containing 
0.5% (v/v) Triton X-100. Cells overexpressing the protein of interest were lysed and the 
lysate was applied to beads containing purified GST-BMPRII or GST-tag alone as    
a negative control. After 1.5 h of incubation at 4 °C with rotation, beads were washed 
three times, and GST-tagged proteins together with bound partners were eluted in 
western blot loading buffer, boiled for 5 min and loaded onto a 12% SDS-PAGE gel. 
 
Lysis Buffer B1: 
20 mM Tris-HCl, pH 7.5 
10 mM EDTA 
5 mM EGTA 
150 mM NaCl 
0.1% (v/v) β-mercaptoethanol 
1 mM PMSF 
 
Washing Buffer B2: 
20 mM Tris-HCl, pH 7.5 
10 mM EDTA 
150 mM NaCl 
0.5% (v/v) Triton X-100 
1 mM PMSF 
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2.2.8.4 Immunohistochemistry 
Expression of particular proteins in human or mouse lung tissue was 
demonstrated using the standard avidin/biotin system according to the manufacturer’s 
instructions (Histostain-SP Kit, Zymed). 
Endogenous peroxidase activity in paraffin-embedded tissues was quenched 
using 1% (v/v) H2O2. After blocking with blocking solution for 10 min sections were 
incubated with primary antibody over-night, followed by a biotinylated secondary 
antibody. Antibody concentrations used for immunohistochemical studies are shown in 
Table 5.6, Appendix. Slides were developed for 5 min with diaminobenzidine (DAB) and 
counterstained with Mayers hematoxyllin.  
 
2.2.8.5 Immunocytochemistry 
Cells were plated in 8-well tissue culture chamber slides and incubated at 37 °C 
for approximately 16 h. Cells were transfected with appropriate expression vectors using 
LipofectamineTM 2000 at 90% confluence. After 24 h of harvesting, cells were washed 
twice with ice-cold 1 × PBS, fixed with 100% methanol for 5 min at -20 °C. After two 
washes with 1 × PBS cells were incubated in blocking solution (5% (v/v) FCS in     
1 × PBS) for at least 1 h at room temperature. The appropriate primary antibody was 
prepared in blocking solution (2.5% (v/v) FCS in 1 × PBS) at dilution 1:100, and 
approximately 300 µl was applied per well. Cells were incubated at room temperature for 
1 h, washed three times with PBS (10 min each), and incubated with FITC-labelled 
secondary antibody at 1:300 dilution in the blocking buffer at room temperature for 1 h. 
After five washes with PBS, the plastic border of the chamber slide was removed, and 
slides were covered with mounting medium containing 4´,6´-diamidino-2-phenylindole 
(DAPI) (1:1000 dilution) for visualisation of nuclei, and samples were analysed by 
fluorescent microscopy. 
 
2.3 Methodology of the yeast two-hybrid system 
The yeast two-hybrid system is a procedure that facilitates the identification of 
novel protein-protein interaction partners, or mapping the domains of interaction 
between two known interacting molecules (Fields and Song 1989). 
The yeast two-hybrid system emerged from studies on eukaryotic transcription 
factors (Figure 2.1), which usually contain separable DNA-binding domains (BD) and 
transcriptional activation domains (AD). The BD is capable of binding to a specific 
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promoter sequence, a region situated upstream from the gene, while the AD directs the 
RNA polymerase II complex to transcribe a downstream gene. Both of these domains 
are required for transcription, but they do not necessarily have to be located on the same 
protein. The BD can activate transcription when simply bound to another protein 
containing an AD (Figure 2.2). This principle forms the basis of the yeast two-hybrid 
technique. 
 
 
Figure 2.1  Principle of normal transcription. 
Normal transcription requires both the DNA-binding domain (BD) and the activation domain (AD) 
of a transcriptional activator (TA) (after Solmaz Sobhanifar et al., 2004). 
 
 
In a two-hybrid assay, two fusion proteins are created: the protein of interest (X), 
which contains a DNA binding domain attached to its N-terminus, and its potential 
binding partner (Y), which is fused to an activation domain. If protein X interacts with 
protein Y, the association of these two proteins will form an intact and functional 
transcriptional activator. This newly formed transcriptional activator will lead to 
transcription of a reporter gene; for which the gene product can be easily detected and 
measured (Figure 2.2). 
 
 
Figure 2.2  Principle of yeast two-hybrid transcription. 
The yeast two-hybrid technique measures protein-protein interactions by measuring transcription 
of a reporter gene. If protein X and protein Y interact, then their DNA-binding domain and 
activation domain will combine to form a functional transcriptional activator (TA). The TA will then 
proceed to transcribe the reporter gene that is paired with its promoter (after Solmaz Sobhanifar 
et al., 2004). 
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In this study, the MATCHMAKER yeast two-hybrid system was employed. This 
system uses an enhanced GAL4 two-hybrid system to detect or confirm protein-protein 
interactions. The GAL4 acts as a transcriptional activator of their target genes by binding 
to upstream activating sequences (UAS) and thus directing RNA polymerase II to the 
corresponding promoters. In the MATCHMAKER system, the yeast strain that was used, 
S. cerevisiae AH109 includes four reporter genes: ADE2, HIS3, lacZ, and MEL1 that are 
under control of distinct GAL4 UAS, while a TATA boxe, provides the binding site for the 
GAL4-DNA-BD. These promoters yield strong and specific responses to GAL4 and thus 
eliminate many false positives and maintain stringency of selection. The MEL1 and lacZ 
genes encode α-galactosidase and β-galactosidase respectively. The α-galactosidase is 
a secreted enzyme and it can be assayed directly on X-α-GAL indicator during the 
screen process. This feature allows the identification of novel protein interactions while 
providing access to the genes encoding the interacting proteins. 
In the two-hybrid screen, the GAL4-DNA-BD is expressed as a fusion product with 
the protein of interest. This is designated the “bait protein”. At the same time, the GAL4-
DNA-AD is expressed as fusion of product with proteins coded in a genomic or a cDNA 
library and is called the “prey”. Therefore, when the bait and the prey interact, the 
interacting proteins activate transcription of the reporter genes as the GAL4-DNA-BD 
and the GAL4-DNA-AD are brought together (Figure 2.3). 
 
 
 
Figure 2.3  Scheme of bait and prey vectors and their protein products. 
The yeast two-hybrid assay uses two plasmid constructs: the bait plasmid, which is the protein of 
interest fused to a GAL4 binding domain, and the hunter plasmid, which is the potential binding 
partner fused to a GAL4 activation domain (after Solmaz Sobhanifar et al., 2004). 
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The properties of plasmids used to express the bait and prey are very important. The 
vectors that are chosen for the two-hybrid screen often are designed to carry different 
antibiotic resistance marker such as ampicillin and kanamycin to allow for their counter 
selection. They also have a nutritional marker specific for a certain amino acids that 
allows the yeast carrying the plasmid to grow on limiting synthetic medium lacking that 
amino acids. Another important portion of the cloning vectors is the truncated ADH1 
promoter. This promoter, truncated or full-length, is used to drive expression of the 
fusion protein in the cloning vector. The full-length ADH1 promoter leads to high-level 
expression of sequences under its control. However, transcription is repressed by the 
high amounts of ethanol that accumulate in the medium as a by-product of yeast 
metabolism. As a result, the vectors that were used in the study all contained some form 
of truncated ADH1 promoter. 
 
2.3.1.1 Bait plasmids constructions 
To generate bait constructs for BMPRII, particular regions of the BMPR2 gene 
encoding the kinase domain, cytoplasmic tail and full intracellular region were cloned into 
the pGBKT7 vector, resulting in a fusion to the GAL4-DNA-BD at the 5' end. Total mouse 
RNA was used as a template in RT-PCR reactions (Section 2.2.2); to isolate particular 
regions of the BMPR2 gene using primers containing restriction sites for EcoRI (forward) 
and BamHI (reverse). Primers sequences are displayed in Table 5.2, Appendix. The 
PCR reaction was carried out according to the protocol in Section 2.2.3. The PCR 
products were digested with EcoRI and BamHI, and separated on 1% agarose gel. 
Bands of 0.9 kb, 1.5 kb, 2.5 kb, were excised and gel-purified. The pGBKT7 vector was 
linearised with the same restriction endonucleases, resolved on a 1% agarose gel, and 
gel-purified in a similar manner. The PCR products from EcoRI and BamHI digestion 
were cloned into the linearised pGBKT7 (Figure 2.4). These ligation products were 
transformed into E.coli DH5α cells, and plated on LB/kanamycin plates. Resulting clones 
were screen with restriction endonucleases for the presence of an insert of the correct 
size. Clones with correct insert sizes after digestion were sequenced to confirm correct 
reading frame. 
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Figure 2.4 The pGBKT7 cloning vector (Clontech). 
The vector generates hybrid proteins, which contain the GAL4-GAL4-DNA-BD at the N terminus 
of the bait. The fusion protein is expressed in the yast host cells from the constitutive truncated 
ADH1 promoter; transcription is terminated at the ADH1 transcription terminator signal. pGBKT7 
also contains the T7 promoter, a c-Myc epitope tag, and a MCS. pGBKT7 replicates 
autonomously in both E. coli and S. cerevisiae from the pUC and 2 µ ori, respectively. The vector 
carries the kanamycin resistance gene for selection in E. coli and the TRP1 nutritional marker for 
selection in yeast.  
 
2.3.1.2 Verification of bait protein expression 
2.3.1.2.1 Transformation of bait constructs into S. cerevisiae AH109 yeast strain 
Bait constructs (0.1 µg) were mixed in a 1.5 ml microcentrifuge tube with 100 µl 
of competent yeast, 0.1 mg herring testes carrier DNA and 600 µl sterile polyethylene 
glycol/lithium acetate (PEG/LiAc) solution. Cells were then incubated at 30 °C for 30 min 
with rotation and after treatment with 70 µl of DMSO, heat-shocked for 15 min in a water 
bath at 42 °C and then incubated on ice for 2 min, after which 100 µl of each 
transformation culture was plated on medium lacking tryptophan (SD/-Trp), and 
maintained at 30 °C for three days. 
 
2.3.1.2.2 Extraction of yeast total protein  
Total protein extracts from S. cerevisiae AH109 transformed with bait constructs 
were prepared by boiling a pellet from 50 ml of yeast culture grown to an OD600~0.6 in 
SD/-Trp. 
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Sample buffer: 
60 mM Tris-HCl, pH 6.8 
10% (v/v) glycerol 
2% (w/v) SDS 
5% (v/v) β-mercaptoethanol  
0.025% (w/v) bromophenol blue. 
 
2.3.1.2.3 Detection of bait protein expression 
For immunoblot analysis, 15 µl aliquots of protein extract were resolved on a 10% 
SDS polyacrylamide gel under reducing conditions, followed by electrotransfer to a 0.25 
µm nitrocellulose membrane. Immunoblotting was performed according to the standard 
protocol (Section 2.2.8.1). 
 
2.3.1.3 Test of the GAL4-DNA-BD/ bait protein for transcriptional autoactivation 
Prior to performing a two-hybrid screen, it is important to verify that the baits 
alone do not activate reporter genes. Therefore, the bait GAL4-DNA-BD fusion 
constructs were independently transformed into S. cerevisiae AH109 and plated on the 
SD/-Trp media containing X-α-Gal. This indicated whether there was autoactivation of 
the lacZ gene by the bait constructs alone. 
The autoactivation of the bait plasmid might occur if the bait plasmid alone acts 
independently as a transcription factor. Autoactivation would have yielded blue colonies. 
A second autoactivation test was performed after mating S. cerevisiae AH109 
transformed with the bait construct and S. cerevisiae Y187 containing an empty prey 
vector. These diploid cells were plated on the SD/-Trp/-Leu media containing X-α-Gal. 
This revealed whether there was autoactivation of the other reporter genes via direct 
interaction of GAL4-DNA-AD domain with the bait protein. Autoactivation would result in 
growth of blue colonies. 
 
2.3.1.4 Gal4-DNA-AD fusion cDNA library 
The mouse 11-day embryo cDNA library was commercially available from 
Clontech. The library was prepared in pACT2 (Figure 2.5, Clontech), which facilitates 
expression of prey proteins as N-terminal fusions to the Gal4-DNA-AD.  
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The library titer was determined to be ≥ 5 x 107/ml and contains 3.5 × 106 independent 
clones with an average DNA insert size of 2 kb. 
The library was prepared by randomly shearing the cDNA obtained by RT and 
using XhoI-(dT)15 primer to attach polylinkers on the ends of each fragment that contains 
EcoRI sites. This permitted use of EcoRI and XhoI for the excision of the inserts from the 
pACT2 from positives colonies. The pACT2 library was amplified in E. coli strain 
BNN132, and the plasmid DNA was isolated and used to transform S. cerevisiae Y187. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 The pACT2 expression vector (Clontech). 
The vector generates hybrid proteins that contain the sequences for the GAL4 activation domain. 
It carries the gene (for ampicillin resistance in E.coli) and the LEU2 nutritional marker that allow 
yeast auxotrophs carring this vector to grow on limiting synthetic medium lacking leucine. The 
hybrid protein is expressed at high levels in yeast host cells from the constitutive ADH1 promoter 
(P); transcription is terminated at the ADH1 transcription termination signal (T).  
 
2.3.2 Screening the pretransformed cDNA library 
2.3.2.1 Yeast mating 
Yeast from 500 ml overnight culture (OD600 >0.8) of the bait strain (S. cerevisiae 
AH109 transformed with the bait construct) were harvested by centrifugation (5 000g,  
20 min, 25°C), and the pellet of the entire culture was combined with the 1 ml 11-day 
embryo cDNA library in a two-litre sterile flask, after which 45 ml of 2 × YPDA medium 
was added, and the culture incubated at 30 °C for 24 h with gentle swirling. 
After 24 h, the mating culture was transferred to a sterile centrifuge bottle and cells were 
harvested by centrifugation at 1 000 g for 10 min. The supernatant was decanted, and 
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the cell pellet was resuspended in 10 ml of 0.5 × YPDA. Cotransformants were plated on 
high-stringency plates (SD/-Trp/-Leu/-Ade/-His/+X-α-Gal) to eliminate backgroun 
2.3.2.2 Identification of positives colonies 
Positives colonies from the screen appeared as blue colonies on selective 
medium after 21 days. These colonies were picked, and the plasmids (a mixture of the 
GAL4-DNA-BD/bait and AD/library) were isolated according to the manufacturer’s 
instructions using Chroma SPIN-1000 DEPC-H2O columns. 
The plasmids were transformed into E. coli DH5α, which were selected for GAL4-
DNA-AD or GAL4-DNA-BD clones by resistance to ampicillin or kanamycin. 
After transformation, bacteria were plated on LB/ampicillin plates. Due to the 
incompatibility of the plasmids, only the one type of plasmid was replicated in each 
bacterial cell. Colonies from ampicillin plates were selected; plasmids were isolated and 
digested with EcoRI and XhoI, and sequenced using the sequencing primer GAL4. 
Nucleotide sequences were translated into amino acids according to the open reading 
frame (ORF) fused to the GAL4 AD sequence, and analysed in GenBank using the 
BLAST algorithm. 
 
2.4 Luciferase assay 
Cells were plated in 48-well dishes (20 000 cells/ well) and after 12 h were 
transfected with 0.2 µg of a different luciferase reporter constructs containing the Id1 
promoter or the BMP-Responsive Element (BRE). Approximately 0.2 µg of pGL3 
luciferase construct was used as reference for transfection efficiency. Cells were 
stimulated for 24 h with BMP (20 ng/ml) or were not stimulated (in the case of control). 
Medium was removed, and cells were lysed using the lysis buffer provided in the Dual 
Luciferase System Kit. After 1 h, cell lysate (40 µl) was added to 50 µl luciferase assay 
reagent in a 96-well plate. Samples were analysed in a Packard Lumicount luminometer. 
 
2.4.1 Microbiological methods 
2.4.1.1 Cultivation of E. coli 
For plating, E. coli cells were spread on LB-agar plates and incubated at 37 °C 
for 8-15 h. For liquid culture, E. coli cells were propagated by vigorous shaking at 37 °C 
in LB medium or LB medium containing the appropriate antibiotic.  
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LB Medium (Luria-Bertani Medium): 
1% (m/v) bacto tryptone 
0.5% (m/v) bacto yeast extract 
1% (m/v) NaCl 
1.5% (m/v) agar* 
 
adjusted to pH 7.0 with NaOH; sterilised for 20 min at 121 °C, 15 psi 
*only for plate preparation 
 
Additives: 
50 µg/ml ampicillin 
30 µg/ml kanamycin  
20 µg/ml X-gal  
0.1 mM isopropyl β-thiogalactopyranoside (IPTG)  
 
2.4.1.2 Preparation of competent E. coli cells for transformation 
Using an inoculating loop, E. coli DH5α were streaked from frozen stock onto the 
surface of an SOB agar plate and incubated for 16 h at 37 °C. Five isolated colonies 
were transferred into 500 ml SOB containing 20 mM MgSO4 and grown at 37 °C to an 
OD600 of~0.4. The cultures were transferred into ice-cold 50 ml polypropylene tubes and 
centrifuged at 2 700 g for 10 min; the pellet was resuspended in 20 ml of ice-cold FSB 
transformation buffer. After 10 min incubation on ice, the cells were recovered by a  
10 min centrifugation at 2 700 g, decanted, and the pellet was resuspended in 4 ml ice-
cold FSB. For frozen stock preparation, 140 µl of dimethyl sulfoxide (DMSO) was added 
twice into 4 ml of resuspended cells. Competent bacteria were stored at -80 °C until 
needed. 
 
FSB transformation buffer: 
10 mM potassium acetate, pH 7.5 
45 mM MnCl2 · 4H2O 
10 mM CaCl2 · 2H2O 
10 mM KCl 
100 mM hexamminecobalt chloride 
10% (v/v) glycerol 
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SOB Medium: 
1% (m/v) bacto tryptone 
0.5% (m/v) bacto yeast extract 
0.05% (m/v) NaCl 
1.5% (m/v) agar* 
2.5 mM KCl 
10 mM MgCl2 (after autoclaving) 
 
adjusted to pH 7.0 with NaOH; sterilised for 20 min at 121 °C, 15 psi 
*only for plate preparation 
 
SOC Medium: 
1% (m/v) bacto tryptone 
0.5% (m/v) bacto yeast extract 
0.05% (m/v) NaCl 
1.5% (m/v) agar* 
2.5 mM KCl 
20 mM glucose (after autoclaving) 
 
adjusted to pH 7.0 with NaOH; sterilised for 20 min at 121 °C, 15 psi 
*only for plate preparation 
 
2.4.1.3 Transformation of plasmid DNA into competent E. coli cells 
An aliquot of competent E. coli cells was slowly thawed on ice and 100 µl of 
highly competent bacteria (1 × 108 cfu/µg DNA) was mixed with 3 µl of plasmid DNA. The 
mixture was incubated on ice for 30 min, followed by heat shock at 42 °C for 1 min, and 
then incubated on ice for 3 min. SOC medium (900 µl) was added, and the mixture was 
further incubated for 1.5 h at 37 °C with shaking. The transformed bacteria were plated, 
and incubated at 37 °C overnight. 
 
2.4.1.4 Plasmid minipreparation 
Individual colonies were picked from LB agar plates and innoculated into 5 ml of 
LB medium containing the appropriate antibiotic. After overnight incubation at 37 °C with 
shaking, the bacterial culture was pelleted by centrifugation at 5 500 g for 8 min and 
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plasmid purification was performed according to the manufacturer’s instruction provided 
together with all reagents in QIAprep Spin Miniprep Kit. 
 
2.4.1.5 Plasmid midipreparation 
According to the protocol from PureYield Plasmid Midiprep System 5 ml of a 4 h 
culture was inoculated into 200 ml of LB medium, pelleted by centrifugation at 5 500 g 
for 15 min and plasmid purification was performed according to the manufacturer’s 
instructions. 
 
2.4.2 Cultivation of yeast  
For plating, yeast cells were streaked on YPD or an appropriate synthetic drop-
out (SD) medium plate and incubated at 27 °C for 12 h-18 days. For liquid culture, yeast 
cells were propagated by vigorous shaking at 27 °C in YPD or appropriate SD medium. 
 
YPD (A)* medium: 
2% (m/v) bacto tryptoneee 
1% (m/v) bacto yeast extract 
3% (m/v) agar (for plates only) 
2% (m/v) glucose 
 
adjusted to pH 6.5 with NaOH; sterilised for 20 min at 121 °C, 15 psi 
*For YPDA medium extra 15 ml of 0.2% (m/v) adenine hemisulfate solution. 
 
SD Medium: 
0.067% (m/v) nitrogen base without amino acids  
DO supplement* 
3% (m/v) agar (for plates only) 
2% (m/v) glucose 
 
pH 5.8 adjusted with NaOH; sterilised for 20 min at 121 °C, 15 psi. 
*amount dependent on the type of DO supplement 
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2.4.2.1 Preparation of competent S. cerevisiae cells for transformation 
S. cerevisiae AH109 or Y187 cells were cultured in YPDA medium to an 
OD600~0.6, then treated with Tris-EDTA/lithium acetate (TE/LiAc) solution. 
 
TE/LiAc buffer: 
1 × TE buffer, pH 7.5 
1 × LiAc  
 
2.4.2.2 Transformation of bait constructs into AH109 yeast strain 
Bait constructs (0.1 µg) were mixed in 1.5 ml microcentrifuge tube with 100 µl of 
competent yeast cells, 0.1 mg herring testes carrier DNA and 600 µl sterile PEG/LiAc 
solution. Then cells were incubated at 27 °C for 30 min with shaking and after treatment 
with 70 µl of DMSO, heat-shocked for 15 min in a water bath at exactly 42 °C and then 
incubated on ice for next 2 min. Aliquots (100 µl) of each transformation culture were 
plated on SD/-Trp medium and maintained at 27 °C for three days. 
 
PEG/LiAc solution: 
40% (m/v) PEG 
1 × TE buffer, pH 7.5 
1 × LiAc  
 
2.4.3 Culture of mammalian cells and transfection technique 
2.4.3.1 Cell culture conditions 
Mammalian cells were grown in tissue culture plates in D-MEM medium   
(NIH/3T3, COS 7, A549) containing 10% (v/v) FBS at 37 °C, 5% CO2 and 95-100 % 
humidity. Each cell line was passaged twice weekly. The cells were washed once with 
PBS, treated with 3 ml trypsin solution for maximum 3 min, resuspended in D-MEM 
medium, and split for further culture. 
 
PBS (phosphate-buffered saline): 
0.08% (m/v) NaCl 
0.02% (m/v) KCl 
0.115% (m/v) Na2HPO4 · 2H2O 
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0.02% (m/v) KH2PO4 · 2H2O 
pH 7.4 adjusted with NaOH; sterilized for 20 min at 121 °C, 15 psi 
 
Trypsin solution: 
0.25% (m/v) trypsin 
1.23 g/l EDTA 
 
2.4.3.2 Transient transfection using LipofectamineTM 2000 reagent 
Transient transfection is a method used to transfer DNA into eukaryotic cells; the 
transfected DNA does not become integrated into the host chromosomes. 
 
Approximately 24 h prior to transfection, cells were plated at cell density     
1-3 × 104/cm2 in complete growth medium to obtain 90% confluence the following day. 
Transfection reagent (LipofectamineTM 2000) was mixed with Opti-MEM I Medium 
without serum and incubated for 5 min at room temperature. The DNA was added, gently 
mixed and the transfection solution was left for 20 min at room temperature to allow 
DNA-Lipofectamine complexes to form. The ratio of DNA to Lipofectamine in OptiMEM 
medium was 1:2.5. 
The transfection mixture was added to plates containing cells in growth medium, mixed 
gently by rocking the plate back and forth. Cells were harvested at 37 °C in a CO2 
incubator for 18-48 h; 4 h after transfection additional, fresh medium was added.  
 
2.4.3.3 Transient transfection of SMC using Nucleofector technology 
Transfection of primary paSMC has been optimized using the Nucleofector 
technology from Amaxa Biosystems. This is a novel and proprietary transfection method 
designed for primary cells and difficult to transfect cell lines. The procedure relies on a 
non-viral method based on a unique (and undisclosed) combination of electrical 
parameters and cell-type specific solutions that transports the DNA directly into the 
nucleus. Using this technology, we routinely achieve 50% to 90% transfection efficiency 
in primary paSMC, which is not possible with several other techniques employed such as 
lipofection or electroporation. In addition, paSMC transfected with this method are viable 
and continue to retain the paSMC phenotype. The transfection was performed according 
to the protocol from Basic Nucleofector Kit; Amaxa.  
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2.4.3.4 Transfection with small interfering RNA (siRNA) 
The paSMC were trypsinised and plated aproximately 24 h prior to transfection in 
complete growth medium to obtain 40-50% confluence the following day. To 
downregulate RACK1, four different siRNA (si#1, si#2, si#3, si#4) against RACK1 were 
tested. Mock (universal negative control siRNA, commercially available from Ambion) 
served as a non-specific siRNA to control possible non-specific siRNA effect. The siRNA 
sequences are available in Table 5.4, Appendix. Transfection reagent (X-tremeGENE 
siRNA) was mixed with Opti-MEM I Medium without serum and incubated for 5 min at 
room temperature, and then individual siRNAs were added (at 100 nM final 
concentration), gently mixed and incubated at room temperature for 20 min. The siRNA-
transfection reagent complexes were added to the cells, and cells were harvested 24 h 
for RNA or 48 h for protein extraction or used for functional analysis. 
 
2.4.3.5 Proliferation assay 
To assess the effect of RACK1 depletion on cell proliferation, paSMC were plated 
in 96-well culture plates at a density of 7.5 x 103 cells/well. The following day, wells were 
treated with (siRNA) Cells were then harvested by trypsinisation, and cells were counted 
using a hemocytometer at the indicated time points. 
In select experiments, cell counts were confirmed by monitoring DNA synthesis by [3H]-
thymidine incorporation assays. Cells were seeded into 96-well plates and treated as 
indicated. Cells were then pulsed with 0.6 µCi of [3H]-thymidine (GE Healthcare, Little 
Chalfont, Buckinghamshire, UK) for 4 h. Plates were washed twice with cold PBS and 
incubated with ice-cold 10% trichloroacetic acid for 30 min at 4 °C. Subsequently, 
samples were solubilised in 0.5 M NaOH. The contents of each well were then 
transferred into scintillation fluid and incorporated radioactivity counted in a liquid 
scintillation counter.  
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 3 Results 
3.1 Identification of new proteins interacting with the 
intracellular region of BMPRII 
3.1.1 Construction and expression of the BMPRII baits 
To identify novel proteins that interact with the intracellular region of BMPRII, we 
conducted a GAL4-based yeast two-hybrid screen (Fields and Song, 1989) (see 
methods 2.3). 
For our analyses, we used as baits the kinase domain of BMPRII (amino acid residues 
205-530 encoded by nucleotides 615-1590), the C-terminal tail domain of BMPRII 
(amino acid residues 530-1038 encoded by nucleotides 1590-3114) and the complete 
intracellular segment of BMPRII containing the kinase and C-terminal tail domains 
(amino acid residues 173-1038 encoded by nucleotides 519-3114). The intracellular 
parts of the receptor were fused to the C-terminus of the GAL4-DNA-binding domain 
(GAL4-DNA-BD) and termed “kinase”, “tail”, and “total” baits, respectively. 
To create these molecules, the appropriate region of the BMPR2 gene was amplified 
with specific primers and cloned in-frame into the pGBKT7 expression vector (Figure 3.1, 
3.2). Plasmid digestion and full-length sequencing were used to confirm that the clone 
would express the desired chimaeric protein (Figure 3.3).  
 
 
 
 
 
 
 
 
Figure 3.1  Graphic representation of the BMPR2 open reading frame (ORF), and 
placement of primers selectively amplifying distinct regions of the gene for yeast two-
hybrid bait construction.  
Amplification of the kinase domain was performed with primers P1 and P2; to obtain cytoplasmic 
tail region primers P3 and P4 were used; the whole cytoplasmic segment of the receptor was 
amplified with primers P5 and P4. Full sequences of those primers are available in Table 5.2, 
Appendix. bp; base pair, SP; signal peptide, TM; transmembrane 
 
 
SP S
Ligand binding  Kinase domain Cytoplasmic tail TM 
bp 1 450 615 1590 3114 78 
P5 
→ 
P3 
 
→ 
P1 
→ 
P2 
← 
P4 
← 
SP 
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Figure 3.2  Amplification of distinct regions of mouse BMPR2. 
Lane 1: Molecular mass markers, lane 2: PCR product encoding the kinase domain of BMPRII, 
lane 3: cytoplasmic tail, lane 4: total intracellular domain. PCR products were resolved on a 1% 
(m/v) agarose gel. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Confirmation of insert ligation. 
Baits constructs were digested with EcoRI and BamHI restriction endonucleases to screen for the 
presence of an insert of the correct size. Digestion of the bait plasmids gave the expected 
fragment sizes Lane 1: molecular mass markers, lane 2: kinase bait (0.9 kb), lane 3: tail bait   
(1.5 kb), and lane 4: total bait (2.5 kb). 
 
 
 
Three bait constructs were transformed separately into S. cerevisiae AH109, and 
transformants were selected for on SD/-Trp media. The proper expression of bait 
constructs was verified by immunoblotting with an anti-Myc tag antibody (Figure 3.4).  
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Figure 3.4  Test for expression of bait proteins. 
A) Schematic representation of bait constructs. B) Immunoblot of protein extracts from     
S. cerevisiae AH109 carrying bait constructs with anti-Myc antibody. Lane 1: extracts of     
S. cerevisiae AH109 carrying an empty vector (pGBKT7) served as a negative control (the 25 
kDa band corresponds to the size of binding domain (BD)), lane 2: extracts of S. cerevisiae 
AH109 carrying kinase bait (50 kDa), lane 3: tail bait (75 kDa), lane 4: total bait (100 kDa). Lower 
molecular mass bands represent degradation products attributable to the high proteolytic activity 
of yeast extracts. BD; binding domain. 
 
3.1.2 Test for autonomous reporter gene activation 
Prior to performing a two-hybrid screen, we verified that the baits alone do not 
activate the reporter genes (Figure 3.5). Empty BD vector, and BD vectors containing the 
apropriate region of BMPR2 were independently cotransformed together with the empty 
AD vector into S. cerevisiae AH109, and plated on SD/-Leu/-Trp media containing   
X-α-Gal. Colonies containing the kinase and total baits appeared as white colonies, 
whereas yeast-containing the tail bait grew as blue colonies, as did those transformed 
with the positive control. We concluded that kinase and total baits did not autoactivate 
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the lacZ reporter gene, whereas the tail bait, due to its autoactivation capacity, was 
excluded from further investigation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5  Test for bait protein autoactivation. 
S. cerevisiae AH109 transfected separately with the three baits constructs were plated on   
SD/-Leu/-Trp media containing X-α-Gal. Section 1: S. cerevisiae AH109 transfected with a 
positive control vector, section 2: with empty BD and AD vector together, section 3: with total 
bait and empty AD vectors together, section 4: with tail bait and empty AD vector, section 5: with 
kinase bait and empty AD vector, section 6: untransfected S. cerevisiae AH109, section 7: 
transfected with empty AD vector, section 8: with empty BD vector alone. 
 
3.1.3 A yeast two-hybrid screen using kinase and total baits 
In order to find novel interacting partners for BMPRII, a mouse 11-day embryonic 
cDNA library was screened using baits expressing the kinase and the total intracellular 
domains of BMPRII. We chose to use this library, as there was no commercially 
available lung cDNA library, and we had observed that BMPRII was highly expressed 
throughout all embryonic stages of mouse development (data not shown). It is also well 
known that BMP signalling is involved in lung development (see Section 1.3).  
S. cerevisiae AH109 either containing kinase or total bait constructs were mated 
with S. cerevisiae Y187 pretransformed with the cDNA library, and were then plated on 
high-stringency medium (SD/-Ade/-His/-Leu/-Trp/ + X-α-Gal) for screening. From         
the 3.5 × 106  independent clones screened, 187 blue colonies indicating putative 
positive interactions, were obtained from the kinase screen, and 168 were obtained from 
the total screen. The clones were individually picked, grown in liquid culture for plasmid 
isolation and sequenced. Insert sequences were translated in the same frame that they 
would have been translated as fusion products with the GAL4-DNA-AD. The translated 
products were subjected to a standard protein-protein blast search against all protein 
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sequences in the NCBI Protein Database. Translated products demonstrating greater 
than 85% homology to known proteins were consider putative true-positive interactions 
(Table 3.1). Other translated products were rejected as false-positives. 
 
Table 3.1  Deduced amino acid sequences obtained from inserts from positive clones. 
The “Ki” clones represent insert sequences obtained from the kinase bait screen, whereas “To” 
clones represent insert sequences obtained from total bait screen. 
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3.1.3.1 Identification of RACK1 as novel interacting partner of BMPRII. 
We observed that the translated sequences of three clones, Ki 42, Ki 56, Ki 97, 
exhibited more than 97% identity with the guanine nucleotide binding protein (G protein), 
β polypeptide 2-like 1 binding protein (Gnb2l1, RACK1). RACK1 is a member of a 
superfamily of proteins containing WD40 domains that are found in a number of 
eukaryotic proteins with a wide variety of functions, including adaptor regulatory 
molecules in signal transduction, pre-mRNA processing and cytoskeleton assembly 
(Figure 3.6). Further sequence analyses revealed that all three clones encode 
overlapping regions of the C-terminal portions of RACK1 from WD4-WD7, suggesting 
these four WD repeats are sufficient for the binding to the kinase domain of BMPRII 
(Figure 3.7). 
 
 
 
 
Results          55 
 
 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Majority
10 20 30 40
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 Ki 42 .PRO
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 Ki 58.PRO
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 KI 97.pro
M T E Q M T L R G T L K G H N G W V T Q I A T T P Q F P D M I L S A S R D K T I  1 RACK1 WT.PRO
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - V I S S D G Q F A L S Majority
50 60 70 80
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - V I S S D G Q F A L S  1 Ki 42 .PRO
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 Ki 58.PRO
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 KI 97.pro
I M W K L T R D E T N Y G I P Q R A L R G H S H F V S D V V I S S D G Q F A L S  41 RACK1 WT.PRO
G S W D G T L R L W D L T T G T T T R R F V G H T K D V L S V A F S S D N R Q I Majority
90 100 110 120
G S W D G T L R L W D L T T G T T T R R F V G H T K D V L S V A F S S D N R Q I  12 Ki 42 .PRO
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 Ki 58.PRO
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 KI 97.pro
G S W D G T L R L W D L T T G T T T R R F V G H T K D V L S V A F S S D N R Q I  81 RACK1 WT.PRO
V S G S R D K T I K L W N T L G V C K Y T V Q D E S H S E W V S C V R F S P N S Majority
130 140 150 160
V S G S R D K T I K L W N T L G V C K Y T V Q D E S H S E W V S C V R F S P N S  52 Ki 42 .PRO
- - - - - - - - - - - - - - L G V C K Y T V Q D E S H S E W V S C V R F S P N S  1 Ki 58.PRO
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - F S P N S  1 KI 97.pro
V S G S R D K T I K L W N T L G V C K Y T V Q D E S H S E W V S C V R F S P N S  121 RACK1 WT.PRO
S N P I I V S C G W D K L V K V W N L A N C K L K T N H I G H T G Y L N T V T V Majority
170 180 190 200
S N P I I V S C G W D K L V K V W N L A N C K L K T N H I G H T G Y L N T V T V  92 Ki 42 .PRO
S N P I I V S C G W D K L V K V W N L A N C K L K T N H I G H T G Y L N T V T V  27 Ki 58.PRO
S N P I I V S C G W D K L V K V W N L A N C K L K T N H I G H T G Y L N T V T V  6 KI 97.pro
S N P I I V S C G W D K L V K V W N L A N C K L K T N H I G H T G Y L N T V T V  161 RACK1 WT.PRO
S P D G S L C A S G G K D G Q A M L W D L N E G K H L Y T L D G G D I I N A L C Majority
210 220 230 240
S P D G S L C A S G G K D G Q A M L W D L - - - - - - - - - - - - - - - - - - -  132 Ki 42 .PRO
S P D G S L C A S G G K D G Q A M L W D L N E G K H L Y T L D G G D I I N A L C  67 Ki 58.PRO
S P D G S L C A S G G K D G Q A M L W D L N E G K H L Y T L D G G D I I N A L C  46 KI 97.pro
S P D G S L C A S G G K D G Q A M L W D L N E G K H L Y T L D G G D I I N A L C  201 RACK1 WT.PRO
F S P N R Y W L C A A T G P S I K I W D L E G K I I V D E L K Q E V I S T S S K Majority
250 260 270 280
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  153 Ki 42 .PRO
F S P N R Y W L C A A T G P S I K I W D L E G K I I V D E L K Q E V I S T S S K  107 Ki 58.PRO
F S P N R Y W L C A A T G P S I K I W D L E G K I I V D E L K Q E V I S T S S K  86 KI 97.pro
F S P N R Y W L C A A T G P S I K I W D L E G K I I V D E L K Q E V I S T S S K  241 RACK1 WT.PRO
A E P P Q C T S L A W S A D G Q T L F A G Y T D N L V R V W Q V T I G T R - Majority
290 300 310
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - N    153 Ki 42 .PRO
A E P P Q C T S L A W S A D G Q T L F A G Y T D N L V R V W Q V T I G T - R    147 Ki 58.PRO
A E P P Q C T S L A W S A D G Q T L F A G Y T D N L V R V W Q V T I G T R .    126 KI 97.pro
A E P P Q C T S L A W S A D G Q T L F A G Y T D N L V R V W Q V T I G T R .    281 RACK1 WT.PRO
Decoration 'Decoration #1': Shade (with solid black) residues that match the Consensus
 exactly.
 
 
Figure 3.6  Sequence alignment of RACK1 from Mus musculus (GenBankTM Accession 
Number NP 032169) and homologous clones from a yeast two-hybrid screen. 
The region of homology with the translated protein sequences of clones Ki 42, Ki 58, and Ki 97 
are shaded. 
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Figure 3.7  Schematic representation of the library clones isolated from the yeast-two 
hybrid screen and full-length RACK1. 
The library clones were identified by direct sequencing and consisted of partial sequence of the 
full-length RACK1. Numbers of amino acids residues are indicated. WD; WD domain. 
 
3.1.4 Confirmation of the BMPRII interaction with full-length RACK1 
using the yeast two-hybrid system 
To verify the interaction of RACK1 with BMPRII, we cloned the full-length RACK1 
cDNA into the pACT2 expression vector and verified the interaction with the kinase and 
intracellular domains of BMPRII. To guard against false-positive results, the library-
derived plasmids (Ki 42, Ki 58, Ki 97) were also re-transformed together with the bait 
plasmids. The interactions between BMPRII and the truncated RACK1 variants encoded 
by Ki 42, Ki 58, Ki 97 and full-length RACK1 were specific, since the growth of the 
colonies on high-stringency selective plates that lacked the nutritional markers adenine 
(Ade) and histidine (His), and contained X-α-Gal was apparent only in the presence of 
both BD-BMPRII and the AD-prey. Yeast transformed with bait plasmid and empty prey 
plasmid, or yeast transformed with library clones and empty bait plasmids were not able 
to grow on high-stringency selective plates (Figure 3.8, middle and right panel). 
Transformation did not alter the growth of the yeast host because all transformants were 
capable of growing on rich, non-selective yeast peptone dextrose (YPD) medium (Figure 
3.8, left panel). 
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Figure 3.8  Interaction between cytosolic domains of BMPRII and full length RACK1 in 
a yeast two-hybrid system. 
Growth of yeast transformants on YPD (complete) medium (left panel), high stringency selection 
plates (middle panel), and high stringency selection plates containing X-α-Gal (right panel).  
AD; activation domain, BD; binding domain, WT; wild type. 
 
 
3.1.5 Confirmation of the interaction between the BMPRII kinase 
domain and the full-length RACK1 by GST pull-down 
3.1.5.1 Overexpression of GST-tagged kinase domain of BMPRII. 
To determine whether the BMPRII, which normally localises to the cell membrane 
as part of a BMPR complex, associates with RACK1, a full-length Myc-tagged RACK1 
was overexpressed in NIH/3T3 cells. Either GST or GST-BMPRII kinase were 
overexpressed in E. coli BL21. 
A bacterial expression system was chosen for overexpression of the BMPRII kinase 
domain fused to the C-terminal end of GST-tag because this system facilitates 
expression and harvesting of a large amount of recombinant protein. Overexpression 
was performed in 27 °C; E. coli BL21 were grown in medium containing 1 mM IPTG. The 
level of protein expression was evaluated at different time points after IPTG induction. 
After 4 h the level of expression reached a plateau. This condition was therefore chosen 
for further experiments (Figures 3.9, 3.10). 
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Figure 3.9  Standardisation of the overexpression condition for the GST-tagged kinase 
domain of BMPRII. 
The E. coli BL21 cell lysates harvested at different time points after IPTG induction were resolved 
on a 12% SDS-PAGE gel, and stained with Coomassie Blue. IPTG; isopropyl β-
thiogalactopyranoside. 
 
  
RACK1 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10  Overexpression of the GST-tagged kinase domain of BMPRII in E. coli BL21. 
Cell lysates from E. coli BL21 transformed either with the empty pGEX-4T1 vector (lane 1) or 
pGEX-4T1 containing the BMPRII kinase domain (lane 2). Lanes 3 and 4 represent the same set 
of cell lysates like in lane 1 and 2 respectively but 4 h after IPTG treatment. Proteins were 
visualised by Coomassie staining. GST cells transfected with empty pGEX-4T1, GST-SF cells 
transfected with pGEX-4T1 containing kinase domain of BMPRII. IPTG; isopropyl        
β-thiogalactopyranoside. 
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3.1.5.2 GST pull-down assay 
Bacterial cell lysates containing overexpressed proteins were incubated with 
gluthathione-Sepharose beads. The proteins bound to the beads were incubated with 
lysates from NIH/3T3 cells. The RACK1 was bound to GST-BMPRII kinase  (Figure 3.11, 
lane 1) but not to GST alone (Figure 3.11, lane 2), demonstrating that BMPRII interacts 
with RACK1 in a GST pull-down. 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11  Verification of the BMPRII kinase domain interaction with RACK1 by GST 
pull-down assay. 
Lane 1 represents the Myc-tagged RACK1 molecule, which interacts with the BMPRII kinase 
fused to the GST. Lane 2 shows no interaction with the GST tag alone (negative control). Lanes 
3 and 4 lack interacting partners due to no overexpression of RACK1-Myc. Expression of RACK1 
and GST and GST-BMPRII kinase is shown on the middle and lower blots. IB; immunoblot. 
 
 
 
3.1.6 Co-immunoprecipitation of BMPRII with RACK1 in a BMP2 
ligand-independent manner 
To further support our contention that an interaction between BMPRII and 
RACK1 occurs in vivo, co-immunoprecipitation of the BMPRII-RACK1 complex was 
performed. The wild-type BMPRII was tagged at the C-terminus with an HA tag, and 
RACK1 was similarly tagged with Myc. The expression constructs encoding these 
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proteins were transfected into NIH/3T3 cells. RACK1 in the lysates of the transfected 
cells was immunoprecipitated with an anti-Myc antibody, and the presence of BMPRII 
was detected with an anti-HA antibody. When the RACK1 was expressed alone and 
immunoprecipitated with anti-Myc antibody, no BMPRII was detected with anti-HA 
antibody by immunoblot (Figure 3.12, lane 2). However, when RACK1 was expressed 
together with BMPRII, both proteins were co-immunoprecipitated by an anti-Myc 
antibody. Stimulation with BMP2 did not influence this interaction. This finding was in 
agreement with the results from the yeast two-hybrid experiments and the GST pull-
down assay, and demonstrates a specific interaction between BMPRII and RACK1 when 
overexpressed in mammalian system. Our data further indicated that this interaction was 
independent of BMP2 stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12  Immunoprecipitation analyses of overexpressed Myc-tagged RACK1 
and its interaction with HA-tagged BMPRII proteins in NIH/3T3 cells. 
The NIH/3T3 cells were transiently transfected with a plasmid encoding BMPRII-HA (lane 3, 4) 
and RACK1-Myc (lane 2, 3, and 4). The cell lysate was immunoprecipitated with anti-Myc 
antibody and bloted with anti-HA antibody to detect BMPRII. Proper and equal expression is 
illustrated on the blot. Lane 1 containing lysate from untransfected NIH/3T3 cells served as 
negative control. IB; immunoblot, IP; immunoprecipitation. 
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3.2 Mapping the region of BMPRII required for RACK1 
binding 
3.2.1 Construction and overexpression of truncated variants of the 
GST-tagged kinase domain of BMPRII 
After confirmation of an interaction between BMPRII and RACK1 we sought to 
determine which region of the cytoplasmic domain of BMPRII was responsible for this 
interaction. 
The GST-BMPRII kinase domain construct was subjected to site-directed mutagenesis 
to reproduce four truncating mutations identified in patients with FPAH. The first 
mutation, Q495X, causes truncation by the replacement of the native glutamine residue 
with a premature stop codon at position 495, a second truncation W466X, was created 
by replacement of tryptophan at position 466 with stop codon. The third mutation at 
position 450, Q450X was obtained via exchange of glutamine with stop codon and the 
fourth mutation, R332X, replaced arginine at position 332 with a premature stop codon 
(Figure 3.13). 
 
 
 
 
 
 
 
 
 
 
Figure 3.13  Schematic representation of BMPRII indicating point mutations that result 
in premature stop codons. 
Sites of stop mutations in the kinase domain are indicated with arrows. AA; amino acid, SP; 
signal peptide, TM; transmembrane domain. 
 
 
The site-mutated constructs were transformed into E. coli BL21 and protein 
expression was induced at 27 °C in LB medium containing 1 mM IPTG. The GST-tagged 
wild-type kinase domain of BMPRII domain was used as positive control for the 
overexpression (Figure 3.14). 
 
205 
 
 
 
 
 
SP Ligand binding  Kinase domain Cytoplasmic tail TM 
AA 1 150 530 1038 
     ↑ 
R332X 
  ↑ 
Q450X 
   ↑ 
W466X 
  ↑ 
Q495X 
Results          62 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14  Overexpression of truncated GST-tagged BMPRII kinase domains. 
Cell lysates from E. coli BL21 bacteria transformed with GST-BMPRII kinase wild-type (lane 1, 6), 
or GST-BMPRII kinase variants prematurely truncated at position 495 (lane 2,7), 466 (lane 3,8), 
450 (lane 4,9), 332 (lane 5,10). Lane 1-5 cell lysates from bacteria that were not induced with 
IPTG, lanes 6-10 stimulated with 1 mM IPTG. Proteins were visualised by Coomassie Blue 
staining. IPTG; isopropyl β-thiogalactopyranoside. 
 
3.2.2 Effect of BMPR2 mutations on the interaction with RACK1 
The ability of these mutated variants to bind RACK1 was assessed by GST pull-
down assay. The GST tagged wild-type kinase domain of BMPRII was used as positive 
control for interaction. Interestingly, none of the truncations abolished the interaction with 
the RACK1 molecule, although all variants exhibited a reduction in binding capacity in 
comparison with GST-tagged wild-type kinase domain of BMPRII (Figure 3.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15  Mapping the BMPRII region required for RACK1 interaction. 
Immunoprecipitation and immunoblot analyses of variants of the GST-tagged kinase domain of 
BMPRII and Myc-tagged RACK1. IB; immunoblot. 
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3.3 RACK1 expression in different mouse tissues 
To investigate a possible function of RACK1 in the lung, we investigated the 
expression of RACK1 in lung tissue (Figure 3.16). For this purpose, we isolated proteins 
from different mouse tissues including the lung and evaluated RACK1 expression by 
immunoblot. It was observed that RACK1 was abundantly expressed in lung tissue as 
well as in other tissues investigated, suggesting an important role of this molecule in 
many cellular processes. 
 
 
 
 
 
 
 
Figure 3.16  RACK1 expression in different mouse tissues. 
Protein extracts obtained from different mouse tissues were probed on an immunoblot for 
expression of RACK1 with an anti-RACK1 antibody. 
 
 
3.4 Expression of RACK1 in a rat model of monocrotaline-
induced pulmonary hypertension 
To assess a potential influence of RACK1 on the pathogenesis of pulmonary 
hypertension, we selected the monocrotaline (MCT) model for further investigations. 
Expression of RACK1 was analysed in rats treated with MCT. The mRNA levels of 
RACK1 in control animals, as well as in animals treated with MCT and sacrified two and 
four weeks after MCT administration was determined by semi-quantitative RT-PCR 
(Figure 3.17 A) and the results were verified by quantitative PCR (Figure 3.17 B). With 
these two methods we detected a significant down-regulation of RACK1 mRNA four 
weeks after MCT treatment. 
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Figure 3.17  RACK1 mRNA expression in lungs from monocrotaline treated rats. 
(A) Changes in expression level of mRNA from four control rats and four monocrotaline-treated 
rats for two and four weeks after monocrotaline administration were assessed by semi-
quantitative PCR. GAPDH served as a control gene. (B) Changes in expression levels of mRNA 
from control and monocrotaline-treated rats were assessed by quantitative PCR. Porphobilinogen 
deaminase (PBGD) served as a reference (house-keeping) gene control. Fold difference in 
mRNA expression from control and monocrotaline treated animals was presented as ∆∆Ct (n=4, 
*p<0.05)  
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Expression of RACK1 was further evaluated at the protein level, and in agreement with 
the observations on mRNA expression levels, RACK1 expression was significantly 
downregulated four weeks after MCT treatment (Figure 3.18). 
 
A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18  RACK1 protein expression in MCT-treated rats. 
(A) Lung proteins extracts from four control and four MCT-treated rats were resolved on a 15% 
SDS-PAGE gel and blot with an anti-RACK1 antibody. The CDK4 protein served as loading 
control. (B) The intensity of the RACK1 signal detected by immunoblot was quantified by 
densitometric analysis (n=4, * p< 0.05). OD; optical density. 
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3.5 Expression of RACK1 in human lungs 
Since RACK1 was downregulated in MCT-treated rat lung tissues, we sought to 
determine if the expression levels differ under pathological conditions in humans. For 
this purpose, we assessed RACK1 mRNA expression in human PAH and donor lungs by 
quantitative RT-PCR. Expression of RACK1 in PAH patients was increased at the mRNA 
level, compared with donor samples (Figure 3.19).  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3.19  RACK1 mRNA expression in lungs of IPAH patients in comparison to 
donors. 
The mRNA from nine donors and twelve PAH patients was assessed by quantitative RT-PCR. 
The porphobilinogen deaminase (PBGD) gene served as a reference (house-keeping) control 
gene. The amount of mRNA is presented by the ∆ Ct (n=4, * p< 0.001). 
 
 
 
The same samples were also tested for RACK1 expression at the protein level by 
the immunoblot. Lung tissue from donors and PAH patients was homogenised and 
proteins were extracted and resolved by SDS-PAGE. The RACK1 was detected with an 
anti-RACK1 antibody. The CDK4 protein served as a control to demonstrate equal 
protein loading. Protein expression levels of RACK1 in the lung did not exhibit significant 
differences between PAH patients and healthy donors (Figure 3.20). 
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Figure 3.20  Protein expression of RACK1 in lungs of IPAH patients and healthy donors. 
Lung protein extracts from six donors and six IPAH patients were resolved on a 15% SDS-PAGE 
gel and blotted to a nitrocellulose membrane and probed with an anti-RACK1 antibody. CDK4 
served as a loading control. 
 
 
3.6 Immunolocalisation of BMPRII and RACK1 in the 
human lung sections 
 
To determine the expression patterns of BMPRII and RACK1 in human lung 
tissues, immunostaining was performed on healthy (donor) and IPAH (patient) lung 
sections. 
The BMPRII staining was detected in endothelial cells and paSMC, similar what 
has been reported previously (Atkinson et al., 2002). The RACK1 was localised to SMC 
with a similar distribution pattern to that seen for BMPRII. Furthermore, we observed a 
clear co-localisation of BMPRII and RACK1 in the concentric leasions of PAH lungs 
(Figure 3.21). The SMA staining served as a marker for SMC localisation. 
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Figure 3.21  Immunohistochemical localisation of BMPRII and RACK1 in human lung 
section.  
Paraffin-embedded specimens from healthy donors (left panel) and patients with IPAH (middle 
and right panel) were stained for BMPRII, RACK1, and smooth muscle actin (SMA).  
 
 
3.7 Co-localisation of endogenous BMPRII and RACK1 in 
human paSMC 
To support the observations made in lung tissue sections immunocytochemical 
staining in human paSMC was also performed. The purity of this cell population was 
verified by SMA staining (Figure 3.22). Staining for BMPRII and RACK1 was performed 
by indirect immunofluorescense using rabbit anti-BMPRII and mouse anti-RACK1 
antibodies (Figure 3.23). The RACK1 exhibited diffuse staining throughout the 
cytoplasm, whereas BMPRII exhibited more membrane and perinuclear localisation. Co-
localisation of these two molecules can be observed as yellow colour. 
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Figure 3.22  Verification of the paSMC phenotype. 
Isolated cells were stained with FITC-labelled (green) for smooth muscle actin (SMA), to verified 
phenotype. DAPI staining (blue) visualised nuclear compartment of the cells. IgG isotype staining 
served as a negative control. 
 
 
 
 
 
   
 
 
 
 
 
Figure 3.23  Co-localisation of BMPRII and RACK1 in human paSMC. 
BMPRII was visualised with an secondary Alexa 549-labelled antibody (red), RACK1 was stained 
with FITC-labelled antibody. Co-localisation results in a yellow colour staining. Cell nuclei were 
visualised with DAPI (blue). 
 
 
3.8 Effects of RACK1 on paSMC proliferation 
 
As paSMC proliferation is a key event in the development of PAH, and since 
RACK1 expression was significantly altered in animal model of PAH, we continued by 
investigating the effect of RACK1 knockdown and overexpression on paSMC 
proliferation. Expression of RACK1 was downregulated using small interfering (si) RNA 
directed against RACK1 (siRACK1). First, it was confirmed that siRACK1 was able to 
reduce RACK1 mRNA levels. Four different siRNA sequences directed against RACK1 
BMPRII RACK1 Merge 
SMA IgG control 
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were tested. Using quantitative RT-PCR we assesed RACK1 mRNA expression levels 
after treatment of paSMC with different siRNA (si#1, si#2, si#3, si#4). Full sequences of 
those oligonucleotides are available in Table 5.4, Appendix. Non-specific siRNA was 
used as a negative control. After transfection with siRNA (si#1, si#2, si#4) we observed a 
significant reduction of mRNA expression in comparison to the mock-treated cells. The 
si#3 sequence directed against RACK1 failed to significantly decrease mRNA RACK1 
levels (Figure 3.24). In agreement with the observation on mRNA levels, the protein 
levels of RACK1 were also potently reduced after treatment with si#1, si#2, and si#4 
(Figure 3.25 ). 
A) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24 RACK1  mRNA expression level after down-regulation with siRNA. 
The mRNA levels of RACK1 in paSMC transfected with different siRNA, assessed by quantitative 
RT-PCR. (n=3 * p< 0.01).  
 
 
 
 
 
B)  
 
 
 
 
 
Figure 3.25 RACK1 proteins expression after down-regulation with siRNA. 
Immunoblot of paSMC protein lysates obtained from paSMC after siRNA treatment. β-actin 
served as a loading control. 
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To analyse whether alteration in RACK1 expression would affect paSMC 
proliferation, [3H]-thymidine incorporation, using paSMC transfected with siRNA directed 
against RACK1, was performed. As depicted in Figure 3.26, the [3H]-thymidine 
incorporation assay demonstrated that knock-down of RACK1 by siRNA results in a 
significant increase in proliferation of paSMC compared to mock-treated cells. These 
data further support a role of RACK1 in the regulation of paSMC proliferation, and 
suggest that perturbations of RACK1 expression and/or function may lead to enhanced 
paSMC cell growth in PAH. 
0
1
2
3
4
 
 
 
Figure 3.26  Increased proliferation of paSMC after RACK1 down-regulation using 
siRNA treatment. 
The paSMC proliferation was assessed by direct [3H]-thymidine incorporation analysis (n=3, * p< 
0.05).  
 
 
The functional outcome of RACK1 overexpression on paSMC proliferation was 
also investigated. The paSMC were transfected by electroporation using RACK1 cloned 
into pcDNA mammalian expression vector. The efficiency of transfection was evaluated 
by flow cytometric analyses using empty or green fluorescent protein (GFP) expression 
vector (Figure 3.27). The effect of RACK1 overexpression on paSMC proliferation was 
assessed by [3H]-thymidine incorporation (Figure 3.28). To further confirm the 
antiproliferative effect of RACK1 overexpression on paSMC, the cell cycle distribution of 
paSMC using flow cytometric analysis was further investigated (Figure 3.29). In 
agreement with previous findings RACK1 overexpression resulted in decreased 
percentage of paSMC in S phase in comparison with cells transfected with empty vector. 
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This observation may explain the anti-proliferative effect of RACK1 overexpression due 
to the blockade of the G1/S cell cycle progression. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27 Transfection efficiency of primary paSMC using the nucleofector 
technology.  
Empty expression vector (EV) or GFP expression vector were transfected into primary paSMC 
and cultured for 24 h. Cells were then trypsinised and analysed for GFP expression by FACS. 
Panels demonstrate a 50% transfection efficiency of primary paSMC. 
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Figure 3.28 Decreased proliferation of paSMC after RACK1 overexpression. 
The paSMC proliferation was assessed by direct [3H]-thymidine incorporation analysis (n=3, * p< 
0.001). EV; empty vector, No stim; no stimulation. Stimulation with PDGF was used as a positive 
control for the assay. 
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Figure 3.29 Decreased percentage of the paSMC in S phase after RACK1 
overexpression.  
After transfection with EV or RACK1, synchronised paSMC were harvested after 24 h, fixed, 
stained, and analysed for DNA content by flow cytometry. The percentage of cells in G0/G1 phase 
(green), S phase (pink) and G2/M phase (blue) are indicated.  
 
 
3.9 Functional effect of RACK1 on BMP signalling 
Using NIH/3T3 cells the functional role of RACK1 on BMP signalling was also 
investigated. The RACK1 was overexpressed in NIH/3T3 cells off the pcDNA 
mammalian expression vector, in a luciferase-based assay that evaluated BMP2 
stimulation. The RACK1 overexpression led to a two-fold increase in luciferase 
expression after BMP2 stimulation, in comparison to the cells transfected with empty 
pcDNA vector (Figure 3.30). RACK1 in involved in regulation of BMP signalling, function 
as a positive regulator for the system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EV RACK1 
DNA content 
Co
u
n
ts
 
G0/G1  68.4% 
S  17.0% 
G2/M 14.8% 
G0/G1  81.1% 
S 9.8% 
G2/M 9.1% 
 
Results          74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30 Increased luciferase activity after RACK1 overexpression.  
Luciferase activation is expressed as a fold-induction between cells treated with BMP2 (20 ng/ml) 
and unstimulated control cells. (n=3, * p< 0.01).
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 4 Discussion 
4.1 The yeast two-hybrid system as a powerful but limited 
tool in our study 
In this study, RACK1 was identified as a novel interaction partner for BMPRII. 
The identification of RACK1 as a binding partner for BMPRII was facilitated using a yeast 
two-hybrid approach. The yeast two-hybrid methodology is widely employed for the 
detection of interacting proteins and to gain insight into protein function and signalling 
pathways. This assay permits the analysis of protein complexes in an intracellular 
setting, and can be used to screen for large numbers of possible interactions. As with 
any technology, the yeast two-hybrid assay has advantages and disadvantages 
compared to the other approaches. The assay tests protein interactions in living cells, 
does not require isolated proteins, and because of the signal amplification afforded using 
enzymes as reporters, the system is also very sensitive and can detect very transient 
protein-protein interactions. However, it remains an artificial system in which the proteins 
under investigation are chimaeric, having been fused to one of two transcription factor 
domains, and are also directed to the nucleus. Additionally, the yeast cell environment 
may not fully mimic that of mammalian cells, due to the lack of some post-translational 
modifications and different subcellular compartments. Some proteins have intrinsic 
transcriptional activation or are inherently “sticky”, false-positives are common, and the 
rationale for eliminating these false-positives is complicated and very important. This 
powerful method requires confirmation with one or more independent methods (Fields 
and Song 1989). However, despite its limitations, the yeast two-hybrid assay has been 
one of the most fruitful tools for discovering and dissecting the function of protein 
interaction. It is estimated that over half of the protein interaction discoveries reported in 
literature originate from yeast two-hybrid investigations (Xenarios and Eisenberg 2001). 
In the past three years, BMPRII has been intensively studied, and using this 
yeast two-hybrid assay, three new interacting partners have already been reported. The 
first molecule was identified during a search for LIM domain kinase 1 (LIMK1)-interacting 
proteins and yielded clones encoding the cytosolic tail region of BMPRII. Further 
analyses revealed that the interaction between LIMK1 and BMPRII inhibited the ability of 
LIMK1 to phosphorylate cofilin, which could then be overcome by the addition of BMP4. 
These interactions alter the dynamics of the actin cytoskeleton (Foletta et al., 2003).  
A second interacting molecule was identified as Tctex1, the light chain of dynein. This 
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molecule binds to, and it is phosphorylated by BMPRII, and is proposed to move along 
the microtubules and interact with downstream mediators of BMPRII, for example Smads 
(Machado et al., 2003). The third interacting partner discovered to date is Src kinase. 
The interaction between BMPRII and Src kinase inhibits Src kinase activity in the 
presence of BMP ligand by preventing its phosphorylation at Tyr418, and further inhibits 
downstream cell cycle regulators, which might influence cell proliferation (Wong et al., 
2005). These discoveries have helped identify novel molecular pathways connecting 
BMPRII and the PAH phenotype. These findings also suggested that BMPRII might have 
important and diverse roles in cellular functions. 
Considering that the major drawback of the yeast two-hybrid system technology 
is the inability to screen libraries with baits containing a transmembrane domain, novel 
BMPRII-interacting proteins were identified in the present study using defined 
intracellular BMPRII domains. These domains included the kinase, C-terminal tail and 
total intracellular domains of BMPRII. Prior to performing the yeast screen, bait 
constructs were examined for proper protein expression and autoactivation. On the 
grounds of autoactivation, the tail bait was eliminated from further investigations. This 
significantly reduced the number of false positive colonies obtained in this study. Positive 
clones were re-transformed into yeast and rechecked for positive interactions with the 
appropriate baits.  
 
4.2 Possible candidates from yeast two-hybrid screen 
To identify novel proteins interacting with BMPRII, we performed a yeast two-
hybrid screen of a mouse embryonic cDNA library using the kinase domain and total 
intracellular segment of the BMPRII as bait. Surprisingly, this screen did not identify any 
of the previously described BMPRII-interacting proteins, including LIMK1, Tctex1, and 
Src. One possible explanation is that a different cDNA library was selected. Furthermore, 
the bait construct containing the C-terminal tail of the BMPRII employed in all previous 
investigations was excluded on grounds of autoactivation, and was replaced with the full 
intracellular region of the receptor. The screen did, however, identify several previously 
unknown interacting partners for BMPRII, and included cytosolic molecules with diverse 
enzymatic activity (eg. glutathione peroxidase factor 1, phosphoribosylaminoimidazole 
carboxylase), nuclear transcription factors (eg. eukaryotic translation elongation factor), 
transmembrane receptors, ion channels (eg. chloride intracellular channel 1). We 
selected for further investigation proteins that we considered most likely relevant to the 
pathogenesis of PAH. 
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4.2.1 PIASy 
Protein inhibitor of activated STAT4 (PIASy), which belongs to a family of 
proteins implicated in the inhibition of cytokine signalling by STAT proteins was identified 
as a putative BMPRII-interacting protein (Sturm et al., 2000). This molecule is also 
known to function as a transcriptional cofactor for nuclear receptors, and small-ubiquitin-
related modifier (SUMO) (Chun et al., 2003; Imoto et al., 2003; Galleguillos et al., 2004) . 
It is known that SUMO is involved in BMP signalling, where it supresses BMP2-induced 
signals. We hypothesised that BMPRII might be modified by sumoylation via interaction 
with PIASy. This BMPRII sumoylation could regulate receptor stability and/or proper 
membrane localisation. Analysing the BMPRII amino acids sequence, several possible 
sumoylation sites were identified (Figure 4.1). 
However, the interaction between BMPRII and PIASy could not be confirmed by an 
independent method, and therefore, this aspect of the study was halted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Possible sumoylation sites in BMPRII. 
Amino acids sequence of BMPRII with possible sumoylation sites indicates motifs with high and 
low probability of sumoylation indicated with different colour. 
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4.2.2 RACK1 as BMPRII-interacting protein 
The most frequently observed protein interacting with BMPRII in the kinase 
screen was identified as RACK1. This interaction was confirmed by two independent 
methods: in vitro GST pull-down and in vivo co-immunoprecipitation. 
The RACK1 protein is a very promising candidate in the context of BMPRII interaction 
partners. It is a 36 kDa cytosolic protein, composed of seven internal WD40 motifs, 
which are predicted to form a seven-bladed β-propeller structure with each blade made 
up of a β-sheet, predicted by crystallographic studies (Ron et al., 1994). Originally, 
RACK1 was identified based on its ability to bind to the activated form of protein PKC, 
stabilising the active form of PKC and permitting its translocation to different sites within 
the cell (Ron et al., 1994; Mochly-Rosen et al., 1995). Interestingly, RACK1 can also 
bind and inhibit Src family kinases (Chang et al., 1998). Through its interaction with PKC 
and Src kinases, RACK1 may function as a critical adaptor protein, mediating cross-talk 
between serine/threonine and tyrosine kinase signalling pathways. Indeed, RACK1 has 
many other binding partners, including integrins (Liliental and Chang 1998), the common 
β chain of the IL-5/IL-3/GM-CSF receptor (Geijsen et al., 1999), phospholipase C-γ and 
RasGAP (Chang et al., 2001), β-spectrin, dynamin (Rodriguez et al., 1999), the protein 
tyrosine phosphates PTPµ (Mourton et al., 2001) and a phosphodiesterase (Yarwood et 
al., 1999). Many reports suggest that RACK1 may act as a scaffolding protein, recruiting 
proteins to various transmembrane receptors and providing the platform for protein-
protein interactions. Proteins that interact with RACK1 fall into two broad categories: 
constitutive, as with the cyclic AMP-specific phosphodiesterase PDE4D5 (Yarwood et 
al., 1999), and stimulus-dependent, such as PKC. The observations presented in this 
study describing a BMPRII and RACK1 interaction represents the constitutive category 
of interaction, and indeed, co-immunoprecipitation studies indicated no influence of 
BMP2 stimulation on this interaction. However, additional BMP ligands should also be 
tested.  
The full range of domains that allow protein partners to interact with RACK1 have 
yet to be determined, however, Src homology (SH2) domains and plekstrin homology 
(PH) domains have already been identified as possible candidates (McCahill et al., 
2002). The present study suggests that the interaction of BMPRII and RACK1 apparently 
involved direct binding of those molecules, but the site of interaction is not yet known. 
None of the identified RACK1-interaction motifs exist in BMPRII, but the fact that diverse 
proteins can physically interact with RACK1 suggested that RACK1 has multiple docking 
sites facilitating interaction with different consesus sequences not yet fully mapped. In 
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addition, the individual blades of the RACK1 β-propeller may be able to direct 
association with specific protein classes. The observation that PH domains and activated 
PKC can bind simultaneously to RACK1 indicates that RACK1 does indeed have 
multiple, independent protein binding sites (Figure 4.2).  
 
The WD repeats of RACK1 are highly conserved across species, including 
plants, genetically malleable insects such as Drosophila melanogaster, higher mammals 
and humans (Vani et al., 1997). Taking this into consideration, and additional data which 
demonstrate that RACK1 is ubiquitously expressed in many tissues of higher mammals 
and humans, including brain, heart, kidney, liver, pancreas, spleen, and lung (Figure 
3.15), it is likely that RACK1 plays an important functional role in many different cell 
types and integration signalling pathways with different physiological functions. 
 
 
 
 
 
Figure 4.2 Propeller blade and WD repeats in a RACK1 structural model. 
(A) The 7-fold β-propeller structure of RACK1; with propeller blades numbered from the N 
terminus and color-coding and residue numbering according to WD repeat sequences.    
(B) Proteins whose interaction with RACK1 has been mapped to particular WD repeats within 
RACK1, indicated by numbering and color-coding. (C) Linear amino acid sequence of human 
RACK1 including residue numbers and WD-repeat color-coding corresponding with those used  
in A (after Ron et al.; 1994). 
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4.3 Implications of RACK1-BMPRII interactions in human 
pathophysiology 
Little is known concerning a functional role for RACK1 in physiology and 
pathophysiology, however, in vivo studies have indicated that RACK1 is up-regulated in 
human carcinomas and during tissue regeneration after ischaemic renal injury 
(Padanilam and Hammerman 1997; Berns et al., 2000). 
The involvement of RACK1 in the control of cellular proliferation and growth implicated 
RACK1 in cancer and in angiogenesis. In agreement with these findings, RACK1 is up-
regulated during all these proceses in vitro and in vivo, and in tissue associated with 
angiogenesis (Berns et al., 2000). 
Thus, the lungs of PAH patients and donors were examined for expression of 
RACK1. Interestingly, expression levels of RACK1 did not exhibit significant differences 
between those two groups at the protein level, although mRNA expression appeared to 
be up-regulated in PAH patients. Similar studies were performed in the lungs of MCT-
treated rats, in which RACK1 expression, both at the mRNA and at the protein levels, 
was significantly reduced when compared with healthy vehicle-treated rats. Two 
possibilities exist to explain these apparently conflicting data. Either the 
pathomechanism of IPAH and MCT-induced PAH are different, or that RACK1 is  
down-regulated during early development of the disease (for example, two and four 
weeks after monocrotaline treatment) while in late-stage chronic disease, compensatory 
mechanisms cause up-regulation of RACK1 expression. 
Although RACK1 levels were not changed under pathological conditions, it has 
already been reported that BMPRII expression in SMC of PAH patients may be 
significantly decreased. Thus, it may well be that loss of the functional BMPRII-RACK1 
interaction occurs not only as a result of BMPRII mutations, but also due to decreased 
levels of BMPRII expression independent on RACK1 expression (Atkinson et al., 2002). 
 
4.3.1 RACK1 function: possible implications for development of 
pulmonary arterial hypertension 
Pulmonary arterial hypertension is characterised by progressive narrowing and 
obstruction of small pulmonary arteries, leading to sustained elevation of pulmonary 
arterial pressure, progressive right heart hypertrophy and eventually, heart failure. 
Pulmonary vascular remodelling is the key pathological hallmark of PAH. Unlike large 
vessel atheromata in the systemic circulation, remodelling of the pulmonary vasculature 
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occurs primarily in small vessels (<500 µm diameter). Reduction in the lumenal area is 
caused by both a reduction in vessel number and by vessel-wall thickening. 
Remodelling, which occurs in all layers of the vessel-wall, includes hypertrophy (cell 
growth) and hyperplasia (proliferation) of vascular cells such as endothelial cells, 
fibroblasts and smooth muscle cells. In addition, remodelling stimulates the deposition of 
connective tissue matrix components such as collagen, elastin and fibronectin. There are 
some differences among animal models and human diseases concerning the degree of 
endothelial cell injury, inflammatory reactions and patterns of vascular smooth muscle 
hypertrophy. However, the process of remodelling is strikingly similar regardless of the 
initiating stimulus, suggesting a stereotypical response to the vascular injury. 
Pulmonary vascular SMC undergo both hypertrophy and hyperplasia. The pattern 
of medial thickening is particularly characteristic of PAH associated with hypoxaemia. 
Smooth muscle hyperplasia results in the extension of proximal smooth muscle into 
distal, normally non-muscularised vessels. An important role of vascular smooth muscle 
in the synthesis of matrix material, such as elastin, which also contributes to the 
thickening of pulmonary vascular media. In precapillary segments, differentiation of 
pericytes and intermediate cells into myofibroblast causes extension of smooth muscle 
cells into partially or non-muscularised small vessels. These cells undergo phenotypic 
shifts towards SMC with characteristic changes in contractile and synthetic properties 
(Tuder et al., 1994; Durmowicz and Stenmark 1999; Jeffery and Morrell 2002; Mandegar 
et al., 2004).  
The mechanisms of pulmonary vascular remodelling are currently the subject of 
intense research. Possible causal factors include physical causes, such as mechanical 
stretch and shear stress, and biological/physiological stimuli such as hypoxia, viral 
infection, vasoactive mediators and growth factors. Remodelling may also result from a 
lack of apoptosis (programmed cell death) of vascular cells or the lack of anti-
proliferative factors. 
The BMPRII plays a major role in mediating vascular smooth muscle and 
endothelial cell proliferation. Abnormalities in BMPRII structure due to mutations found in 
PAH patients might be expected to cause abnormal vascular cell proliferation. The 
RACK1 protein, selected by us as a new candidate for interaction with BMPRII, functions 
at the hub of a large array of signal transduction cascades that influence all cellular 
processes (proliferation, migration and cell growth), and loss of this interaction may 
therefore contribute to the pathogenesis of PAH. 
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4.3.1.1 Regulation of G1/S cell progression and cellular growth 
It has been demonstrated that RACK1 can prolong the G0/G1 phase of the cell 
cycle by inhibiting the activity of Src, and thereby the downstream cell cycle regulators 
including Myc, Stat3, Rho GTPases, and Vav2. Thus, overexpression of RACK1 causes 
suppression of cyclin D1, CDK4, and CDK2, activation of p27 and retinoblastoma, E2F1 
is sequestered, and G1/S progression is delayed. Conversely, siRNA inhibition of RACK1 
expression activates Src-mediated signalling and accelerates G1/S transition 
(Mamidipudi et al., 2004). Consequently, cells overexpressing RACK1 exhibited 
decreased growth rates by 40-50% compared with control cells transfected with empty 
vector (Mamidipudi et al., 2004). 
 
4.3.1.2 Regulation of integrin-mediated adhesion and chemotactic cell migration  
The RACK1 is also an important regulator of focal adhesion organisation, cell 
spreading, and migration. The effects of RACK1 on cell migration are at least in part 
mediated through the Src binding site of RACK1. Expression of RACK1 Y246F, a variant 
that does not bind to Src, induced a loss of central cellular adhesions, and inhibited 
chemotaxic cell migration. Interestingly, the Src binding site was critical for RACK1-
mediated effects on protrusion and chemotactic cell migration, but not on random or 
haptotactic motility. This indicates that the Src binding site of RACK1 is not necessary for 
basal cell motility but is required specifically for directional motility during chemotaxis. 
This points to the interesting possibility that RACK1 may mediate cross-talk between 
growth factor receptors and integrins to promote directional migration towards 
chemotaxic gradients (Cox et al., 2003).  
 
4.3.1.3 Regulation of protein kinase C and integrin-dependent cell migration 
Cells stably or transiently overexpressing RACK1 have decreased migration 
compared to mock-transfected cells. The RACK1 transfectants also demonstrate an 
increased number of actin stress fibers and focal contacts. This effect on motility and 
cytoskeletal organisation did not result from RACK1 inhibition of Src. An active form did 
not reverse the migratory deficiency induced by RACK1 overexpression whereas 
overexpression of a variant with alanine substitutions in the putative PKC binding site in 
the third WD binding region exhibited no altered migration (Buensuceso et al., 2001). 
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4.3.1.4 Regulation of cell proliferation 
The interaction between BMPRII and Src tyrosine kinase may inhibit Src tyrosine 
kinase activity in the presence of BMP ligand by reducing its phosphorylation at Tyr418. 
Inhibition of Src may consequently inhibit downstream cell cycle regulators such as 
cyclins D and E and subsequently prevent SMC proliferation. The inhibitory effect of 
BMP signalling on Src phosphorylation may oppose the growth signals of such 
mediators as 5-HT and PDGF, by down-regulation of cell cycle regulators. 
Taking in to consideration all these data combined with our findings we can 
speculate that RACK1 might play important role in regulation of paSMC proliferation. 
Lost of these control might result in uncontrolled paSMC proliferation, vessels occlusion 
and finally development of PAH. 
 
4.3.2 The paSMC and RACK1 
Immunohistochemical studies performed in lung sections from normal and PAH 
patients demonstrate that BMPRII and RACK1 are expressed in the SMC of pulmonary 
arteries and arterioles. Co-localisation of these two molecules in the key site of 
pathogenic vascular remodelling observed in PAH adds weight to the potential 
importance of this protein in combination with BMPRII in maintaining the normal 
pulmonary vascular state. This finding was also confirmed by immunocytochemistry on 
freshly isolated paSMC, where the presence of these two molecules in the same SMC 
was observed.  
To further determine whether PAH-associated mutations in BMPR2 affect the 
interaction with RACK1, several truncated forms of the receptor containing nonsense 
mutations in the kinase domain of the BMPRII were tested for their ability to interact with 
RACK1. Surprisingly, all mutated forms of the receptor were still able to interact with 
RACK1, but the strength of the interaction was weaker. Every mutation in the kinase 
domain that generated a truncated form of BMPRII caused loss of efficiency in the 
binding of BMPRII to RACK1. The region between amino acids 495-530 of the kinase 
domain appeared to contain an important element required for stabilisation of this 
interaction. Alternatively, this region is important for folding of the receptor allowing for 
efficient interaction with RACK1. Although the expression levels of RACK1 are not 
altered in PAH, the possible loss of interaction with a truncated BMPRII might result in 
decreased BMPRII signalling. 
Taken together, it appeares that mutations in BMPR2 do not completely abolish the 
interaction between BMPRII and RACK1, but rather change the intensity of this 
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interaction, which consequently effects downstream signalling, and ultimatelly 
contributes to the pathogenesis of PAH. Furthermore, in agreement with the observation 
in the previous study that RACK1 requires the full-length kinase domain for efficient 
interaction, while the tail does not seem to influence this binding.  
Interestingly, abrogation of RACK1 expression by siRNA treatment resulted in 
significantly increased paSMC proliferation, whereas overexpression of RACK1 
decreased paSMC proliferation. Taken together, these functional data derived from 
paSMC clearly point towards a key regulatory role of RACK1 in paSMC growth. A 
decrease in RACK1 expression, or a decreased RACK1/BMPRII interaction (in case of 
BMPRII mutations) can lead to increased smooth muscle cell proliferation, a key finding 
in the pathophysiology of PAH. While we do not propose that this is a dominant 
mechanism in all PAH patients, our data suggests that this may contribute to PAH 
pathogenesis in those patients with BMPRII mutations that lead to a truncation and/or 
loss of the BMPRII kinase domain. 
 
4.4 Possible models for the involvement of RACK1 in the 
development of pulmonary arterial hypertension 
Taking into consideration the model of interaction between BMPRII and c-Src 
proposed by Wong (Wong et al., 2005), together with the findings presented in the 
present study, it seems possible that RACK1 is an adaptor protein that is responsible for 
cross-talk between serine threonine kinases, which brings Src kinase and BMPRII 
together. The interaction between BMPRII and c-Src tyrosine kinase may inhibit c-Src 
tyrosine kinase activity in the presence of BMP ligand by reducing its phosphorylation at 
Tyr418 residue. The inhibition of c-Src activity by BMP signalling may inhibit downstream 
cell cycle regulators such as cyclins D and E and subsequently prevent SMC 
proliferation. Under pathological conditions, when RACK1 or BMPRII expression levels 
are decreased, or due to BMPR2 mutations where RACK1 binds less efficiently to the 
receptor, which would alter Src activation, and may result in uncontrolled cell 
proliferation. 
To determine the functional role of the interaction between BMPRII and RACK1, 
alternative functions of RACK1 in BMP signaling can be proposed. Although, the 
BMPRII-RACK1 interaction was ligand-independent, when RACK1 was overexpressed 
in a luciferase reporter assay using a BMP-responsive promoter (pId 270). RACK1 
overexpression led to a two-fold increase in luciferase expression after BMP2 
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stimulation. These findings suggest that RACK1 is functionally significant in BMP signal 
transduction, for example, as a molecule required for receptor heterocomplex formation. 
These data suggest a potential role for RACK1 in the pathogenesis of PAH, which 
requires additional experimental demonstration. 
 
4.4.1 BMP signalling and pulmonary arterial hypertension 
The majority of cardiovascular abnormalities including PAH are associated with 
molecular, cellular, and histological alterations to the vasculature, a system ultimately 
defined by a single cell layer of endothelium, surrounded by vascular smooth muscle 
cells (VSMC), and adventitial tissue. Physiologically, vessel architecture and function is 
tightly controlled by a network of soluble mediators, cell-cell, and cell-matrix interactions. 
Many of the processes regulated by soluble factors act in a paracrine fashion on 
vascular wall-resident cells (Owens et al., 2004; Clark et al., 2005). Amongst these 
factors, members of the TGFβ superfamily, including TGFβs and BMPs are the most 
pleiotropic mediators and, due to the ubiquitous expression of their receptors, exhibit a 
series of effects on cells within the vascular system. In recent years, our knowledge 
about the signal transduction mechanisms of TGFβ superfamily members, and the 
diseases associated with perturbations to it has expanded considerably (Massague and 
Wotton 2000; Massague 2003; Massague et al., 2005). The TGFβ/BMP ligands are 
among the key factors controlling vessel physiology and pathology through multiple 
effects on differentiated and precursor endothelial cells, VSMC, myofibroblasts, and 
interstitial fibroblasts. The TGFβ and BMP isoforms essentially control endothelial and 
VSMC proliferation, as well as extracellular matrix (ECM) secretion and deposition by 
these cells (Seay et al., 2005). Knock-down animals for most members of the TGFβ 
superfamily are embryonically or perinatally lethal, and most of these animals exhibit 
severe defects in vasculogenesis [i.e. the TGFβ, TβRΙ (ALK5), ALK1, and Smad5 knock-
downs]. In addition to its importance for normal embryogenesis, organogenesis, and 
development, perturbations to the TGFβ system have been associated with multiple 
cardiovascular diseases, such as atherosclerosis, myocardial fibrosis and pulmonary 
hypertension (Eickelberg et al., 2003). 
The important roles for the TGFβ superfamily in endothelial and SMC growth, 
differentiation and matrix production reinforced the potential role of BMPRII in the 
vascular lesion of PAH. Disruption of TGFβ superfamily signalling as a consequence of 
BMPR2 mutations and down-regulation of BMPRII expression observed under 
pathological conditions and down-regulation of BMP signalling in hypoxia-induced PAH 
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in rats and in the cell lines transiently transfected with mutant BMPR2 might contribute to 
the cellular proliferation and vascular obliteration seen in these condition (Takahashi et 
al., 2006). In the context of these findings, transient overexpression of RACK1, which 
has been identified in the present study as a novel interacting partner for BMPRII, led to 
two-fold increase in the activity of a luciferase reporter construct containing a BMP-
responsive Id promoter. From these findings, it appears that the presence of RACK1 is 
required for optimal BMP signalling, and lack of RACK1, or loss of, or decresaed 
intensity of the BMPRII-RACK1 interaction may lead to the reduction in BMP signalling 
commonly observed in PAH condition.  
 
4.4.2 BMP signalling and vascular remodelling 
Precise control of apoptosis and proliferation of paSMC plays a critical role in 
maintaining normal pulmonary vascular structure and function. In patients with PAH, 
hypertrophy of the pulmonary vascular wall and obliteration of small pulmonary arteries 
are the major causes of the elevated pulmonary vascular resistance and pulmonary 
arterial preassure (PAP). The pulmonary vascular remodelling is characterised by medial 
hypertrophy due to smooth muscle growth and is one of the most important factors 
contributing to the narrowing of the vascular lumen and increased the pulmonary 
vascular resistance. 
Many vasoactive agonists, growth factors, and cytokines including BMPs regulate 
paSMC proliferation. Because mutations in the BMPR2 gene have been found in familial 
and sporadic PAH patients, it is important to elucidate the physiological role of the BMP 
signalling system in the regulation of normal paSMC, and to define the BMP-mediated 
effects on paSMC from PAH patients. 
The role of BMPs in pulmonary vascular remodelling is not easy to predict, 
because members of the TGFβ superfamily of ligands exert complex effects on vascular 
cell function, which vary depending on the cell phenotype and context. The main 
reported effects of the TGFβ on vascular cells are growth inhibition, cell differentiation 
and stimulation of collagen synthesis (McCaffrey 2000). The BMPs have been less 
extensively studied, but BMP7 has been shown to inhibit proliferation of human aortic 
SMC and increased expression of smooth muscle differentiation markers, and BMP2 
inhibited vascular SMC proliferation after balloon injury in rats (Nakaoka et al., 1997; 
Dorai et al., 2000). Morrell et al. also demonstrated that BMP2, 4, and 7 inhibited the 
proliferation of SMC derived from normal pulmonary arteries and from patients with 
secondary PAH to congenital heart disease, but failed to suppress proliferation of cells 
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from patients with PAH. An attractive hypothesis is that a failure of the growth-inhibitory 
effects of BMPs of cells from PAH patients could contribute to the vascular obliteration 
and remodelling that characterise this condition. Interestingly, the failure to suppress 
growth of cells from PAH patients was observed in all cells from PAH patients, whether 
or not specific BMPRII mutations were identified, suggesting that defective BMP-
mediated signalling might be a common factor in PAH (Morrell et al., 2001).  
 
4.5 Conclusions and future perspectives 
This study tested the hypothesis that novel interaction partners of BMPRII are 
essential regulators of smooth muscle cell proliferation, a key finding in PAH. The basis 
of this hypothesis was the observation that up to 50% of patients with familial PAH 
exhibit germline mutations in BMPR2, the gene locus encoding BMPRII. Despite this 
overwhelming genetic evidence for a causal involvement of BMPR2 mutations in PAH 
pathogenesis, it is still unclear about the precise mechanisms that give rise to such a 
localised disease in the setting of a germline mutation, which leads to the expression of 
the mutant BMPRII protein throughout the body. As most mutations described thus far 
are localised to the intracellular domain and predicted to lead to a truncation of the 
BMPRII protein, a loss and/or gain of function due to the specific mutations is proposed 
to be involved in PAH pathogenesis. Indeed, several recent publications have indicated 
that BMPRII mutations can alter intracellular signaling by p38 kinase or Smad proteins 
(Yang et al., 2005; Yu et al., 2005), although there is considerable discussion on whether 
BMPRII mutations or its allelic loss increases or decreases Smad signalling. In addition 
to this idea, truncations of BMPRII could also result in the gain/loss of interaction of an 
as yet unknown binding partner of BMPRII, in a ligand-dependent or-independent 
manner. Therefore, the aim of this study was to uncover novel BMPRII-interacting 
proteins, elucidate their function in paSMC, and investigate their localisation and 
expression in healthy and diseased lungs. 
In summary, the present study identified RACK1 as a novel interaction partner for 
BMPRII using the yeast two-hybrid system. This novel interaction was confirmed by GST 
pull-down and co-immunoprecipitation in mammalian cells and occurred in a BMP2-
independent manner, suggesting a constitutive interaction involved in basal maintenance 
of the smooth muscle phenotype. Further, it was also reported that the ability of RACK1 
to bind to BMPRII is significantly reduced by mutations associated with PAH, which 
cause a truncation of the protein in the kinase domain. Finally, co-localisation of both 
BMPRII and RACK1 within paSMC, a prominent site of pathological remodelling in PAH, 
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was demonstrated, together with the functional relevance of RACK1 expression on cell 
proliferation. 
The plethora of cellular functions in which RACK1 has been implicated reflects 
the ability of this scaffolding protein to interact with a wide range of signalling proteins. 
Analogous to Cpc2 in yeast cells, mammalian RACK1 seems to direct cross-pathway-
control by integrating communication from different signalling pathways. 
These data lay the foundation for future investigations into the link between the 
BMP system, RACK1 and PAH and provides a new dimension to the complexity of BMP 
signalling and PAH which must be further elucidated.  
In conclusions genetic association studies and functional genetic analyses 
strongly support BMPR2 as a key genetic determinant of PAH, and other genetic factors 
undoubtedly play a role in the pathobiology of the disease, and its phenotypic 
expression. The incomplete penetrence of the disease and its genetic anticipation in 
families bearing mutations suggest that other genetic factors and, or environmental 
exposure contribute to the disease pathogenesis. Carrying a mutation in BMPR2 does 
not ensure that one will invariably develop the disease: other factors appear to be 
required that are determined by other genes or environmental factors. While these 
investigations have all led to an increased understanding of BMPRII functions, we are 
now at a stage where novel BMPRII interaction partners play a role in pathologic smooth 
muscle cell funtions such as proliferation, with direct relevance to disease. 
To further study the aetiology of PAH, the detailed analyses of the functional 
interaction of BMPRII with a novel partner, RACK1, and its potential role in PAH has to 
be performed, together with the whole genome expression studies in paSMC with 
targeted overexpression or knock-down of RACK1 (using mammalian expression vectors 
and siRNA technology, respectively). These studies should be complemented by whole 
genome location analysis using chromatin immunoprecipitation, thus identifying direct 
target genes of the BMP-Smads1/5. To combine state-of-the-art molecular biological and 
cell biological methods to analyse in vitro and in vivo roles of the aforementioned system 
constituts our future directions. 
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 5 Appendix 
Table 5.1  List of BMPR2 gene polymorpisms identified in PAH patients to date  
Abbreviations: ECD; extracellular domain, TM; transmembrane domain, KD; kinase domain, CD; 
cytoplasmic domain (after Machado et al., 2006). 
 
Location Domain Amino acid change Comments 
Exon1  L5fsX29  
Exon1  P8fsX27  
Exon1  W9X  
Exon1  P15fsX31  
Exon1  W16X  
Exon2 ECD A26Q82del  
Exon2 ECD E31X  
Exon2 ECD C34R  
Exon2 ECD Y40X  
Exon2 ECD Q42R  
Exon2 ECD G47N  
Exon2 ECD H53fsX  
Exon2 ECD T57fsX20  
Exon2 ECD C60Y  
Exon2 ECD S64W70 del  
Exon2 ECD C66Y  
Exon2 ECD C66R  
Exon2 ECD Y67C  
Exon2 ECD G68D  
Exon2 ECD S73X  
Exon2 ECD Q82X  
Exon2 ECD Q82H  
Exon2 ECD W85X  
Exon3 ECD Q92X  
Exon3 ECD C94R  
Exon3 ECD C99R  
Exon3 ECD T102A  
Exon3 ECD S107P  
Exon3 ECD C117Y  
Exon3 ECD C117S  
Exon3 ECD C118Y  
Exon3 ECD C118W  
Exon3 ECD S119fsX132  
Exon3 ECD P120fsX  
Exon3 ECD C123S  
Exon3 ECD C123R  
Exon4 ECD R147X 
 
Exon4 TM P169fsX12  
Exon5 TM G182D  
Exon5 TM M186V  
Exon6 KD R211X 
 
Exon6 KD R213X 
 
Exon6 KD S221fsX3  
Exon6 KD L222fsX7  
Exon6 KD K230fsX25  
Exon6 KD KK230fsX21  
Exon6 KD E243X  
Exon6 KD R259fsX2  
Exon6 KD G263fsX2  
Exon6 KD D265fsX13  
Exon6 KD R266T  
Exon6 KD M273R  
Exon7 KD G285fsX5  
Exon7 KD S301P  
Exon7 KD R303H  
Exon7 KD A313P  
Exon7 KD R321X  
Exon7 KD D323fsX  
Exon8 KD P327fsX7  
Exon8 KD R332X 
 
Exon8 KD L334X  
Exon8 KD C347R  
Exon8 KD C347Y  
Exon8 KD T359fsX15  
Exon8 KD G367fsX3  
Exon8 KD N371fsX3  
Exon8 KD I374fsX  
Exon9 KD C397fsX  
Exon9 KD S399X  
Exon9 KD L401S  
Exon9 KD Q403X  
Exon9  KD W414X  
Exon9 KD I416fsX3  
Exon9 KD F417fsX1  
Exon9 KD R419S  
Exon9 KD C420R  
Exon9 KD C420Y 
 
Exon9 KD P425fsX22  
Exon10 KD T438fsX34  
Exon10 KD Q450X  
Exon10 KD R459fsX9  
Exon10 KD E459fsX10  
Exon10 KD E464fsX6  
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Exon10 KD W466X  
Exon10 KD E468fsX5  
Exon11 KD L476fsX29  
Exon11 KD C483R  
Exon11 KD D485G  
Exon11 KD A490V  
Exon11 KD R491W 
 
Exon11 KD R491Q 
 
Exon11 KD Q495X  
Exon11 KD C496Y  
Exon11 CD E503D  
Exon11 
Exon11 
CD 
CD 
K512T 
N519K 
 
Exon11 CD R529fsX34  
Exon12 CD V563M  
Exon12 CD R584X  
Exon12 CD T652fsX6  
Exon12 
Exon12 
CD 
CD 
V654fsX5 
L658fsX48 
 
Exon12 CD Y708X  
Exon12 CD N764fsX48  
Exon12 CD T766fsX5  
Exon12 CD A796fsX6  
Exon12 CD V804fsX3  
Exon12 CD T836fsX  
Exon12 CD A846fsX15  
Exon12 CD N861fsX10  
Exon12 CD R873X 
 
Exon12 CD E874X  
Exon12 CD R899X 
 
Exon12 CD R899P  
Exon12 CD N903S  
Exon12 CD S930X  
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Table 5.2  List of primers used for PCR amplification.  
M; mouse, H; human, KD; kinase domain, CD; cytoplasmic domain, ID; intracellular domain,   
T; temperature, bp; base pair, bold nucleotides represent restriction sites incorporated to the 
primers. 
 
GenBankTM 
(Accesion number) 
Forward Primer 
(5´ to 3´) 
Reverse Primer 
(5´ to 3´) 
Annealing 
T (°C) 
Amplicon 
Size (bp) 
mBMPRII 
(NM_007561) 
TAC AGA ATG TTG ACG 
ACA GGA GAC CGG 
TCA CAG ACA CAA TTC ATT CCT 
ATA TC 
58 3180 
mBMPRII KD (P1,P2) 
(NM_007561) 
GAC CTG GAA TTC CTG 
AAG CTG CTG GAG 
CTC CCA GGA TCC TCA GAG 
TTC AGC CAT CCT 
60 900 
mBMPRII CD (P3,P4) 
(NM_007561) 
AAT GAA GAA TTC CTG 
TCA CAT AAT AAG 
CTT GAA GGA TCC TCA CAG 
ACA ATT CAT 
60 1500 
mBMPRII ID (P5,P4) 
(NM_007561) 
TTA TGT GAA TTC TAC 
AGA ATG TTG ACA 
CTT GAA GGA TCC TCA CAG 
ACA ATT CAT 
58 2500 
mPIASy 
(NM_021501) 
CAA GAT GGC GGC AGA 
GCT GGT 
CGA GGG AAT GAT GGA CGG 
GTG 
60 1500 
mPIASy 
(NM_021501) 
GGA ATT CGG ATG GCG 
GCA GAG CTG GTG 
CTG CTC GAG CTA CTT GTC 
CTG CAT 
60 1500 
mRACK1 
(NM_008143) 
TAT CCG GTG CCA TCC 
TTG TCG 
CC AGG GAC TCA GCT TCC AGG 
ACT 
58 950 
mRACK1 
(NM_008143) 
GAATTCGGATGACCGAGC
AGATGACCCTT 
AAGCTTGCGGGTACCAATAGTTA
CC 
60 950 
mRACK1 
(NM_008143) 
CC ATG GGG ATG ACC 
GAG CAG ATG ACC CTT 
GAA TTC TTA GCG GGT ACC 
AAT AGT TAC 
60 950 
mRACK1 
(1-154aa) 
(NM_008143) 
G AAT TCA TGA CCG AGC 
AGA TGA CCC 
A AGC TTG ACC GAG CAG ATG 
ACC 
57 460 
mRACK1 (154-
317aa) 
(NM_008143) 
GAA TTC ATG CGC TTC 
TCC CCG AAC ACG 
AAG CTT GCG GGT ACC AAT 
AGT TAC CTG 
60 490 
mRACK2 
 
AT GAC GGC AGC CGA 
GAA GTG 
TAG ACT AGT CTT CTT TTG AGA 
 
56 2500 
hRACK1 
(NM_008143) 
AA CCC AGA TCG CTA 
CTA CCG 
CC CAG GAG CCT GAG AGG 
GCA 
58 200 
mRACK1 
(NM_008143) 
CT CAA GGG CCA TAA 
TGG ATG 
TC GAA GAG CAC GTT GTA 60 150 
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Table 5.3  List of primers used for site-directed mutagenesis.  
T; temperature, bold nucleotides represent exchanged nucleotides incorporated to the primers. 
 
Primer name Forward primer sequence 5´-3´ Reverse primer sequence 5´-3´ Annealing 
T (°C) 
Q495X GCT CGG CTC ACT GCA TAG TGT GCT 
GAG GAG AGG 
CCT CTC CTC AGC ACA CTA TGC 
AGT GAG CCG AGC 60 
W466X AAG TTC CCA GAA GCC TAG AAA GAA 
AAT AGC CTG 
CAG GCT ATT TTC TTT CTA GGC TTC 
TGG GAA CTT 60 
Q450X ACA TTT GAG GAT ATG TAG GTT CTT 
GTG TCC AGA 
TCT GGA CAC AAG AAC CTA CAT ATC 
CTC AAA TTT 60 
R332X CCC GCA ATC TCC CAC TGA GAT TTA 
AAC AGC AGG 
CCT GCT GTT TAA ATC TCA GTG GGA 
GAT GGC GGG 60 
 
 
Table 5.4  List of siRNA sequences designed against RACK1. 
 
siRNA name Sense sequence 5´-3´ Antisense sequence 5´-3´ 
si #1 CAA AUA CAC UGU CCA GGA UUU AUC CUG GAC AGU GUA UUU GUU 
si #2 GAU AAG ACC AUC AUC AUG UUU ACA UGA UGA UGG UCU UAU CUU 
si #3 CCA AGG AUG UGC UGA GUG UUU ACA CUC AGC ACA UCC UUG GUU 
si #4 GAG AUA AGA CCA UCA UCA UUU AUG AUG AUG GUC UUA UCU CUU 
 
 
Table 5.5  Table of vectors and restriction sites used for cloning. 
 
Construct name  Gene name Vector name, Company  Restriction sites 
RACK1Myc RACK1 pCMV5A;Stratagene, USA EcoRI; HindIII 
RACK1 RACK1 pcDNA(-); EcoRI; HindIII 
R1-154 RACK1 pCMV5A;Stratagene,USA EcoRI; HindIII 
R154-317 RACK1 pCMV5A; Stratagene,USA EcoRI; HindIII 
AD-RACK1 RACK1 pACT2; Clontech; USA NcoI;EcoRI 
BD-BMPRII kinase BMPRII pGBKT7;Clontech,USA EcoRI; BamHI 
BD-BMPRII tail BMPRII pGBKT7;Clontech,USA EcoRI; BamHI 
BD-BMPRII total BMPRII pGBKT7;Clontech,USA EcoRI; BamHI 
GST-BMPRII kinase BMPRII pGEX4T1;Amersham,Germany BamHI;EcoRI 
BMPRII Full-length BMPRII pCMV-HA, Stratagene;USA ApaI 
Flag-PIASY PIASy pCMV2C; Stratagen,USA EcoRI; 
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Table 5.6  List of antibodies used for immunoblot (IB), immunohistochemistry (IHCH), 
and immunocytochemistry (ICCH). 
 
Antibodies 
 
Host  Dilution  Company 
Primary antibody  IB IHCH ICCH  
anti-BMPRII goat 1:1000 1:50 1:50 Santa-Cruz Biotech 
anti-Flag  rabbit 1:2500   Sigma-Aldrich 
anti-GFP mouse 1:1000   Santa-Cruz Biotech 
anti-HA Tag mouse 1:1000   Cell Signaling 
anti-HA Tag mouse 1:2500   Sigma-Aldrich 
anti-HA Tag rabbit 1:2500   Sigma-Aldrich 
anti-Lamin A/C rabbit 1:10000   Santa-Cruz Biotech 
anti-Myc Tag mouse 1:4000   Sigma-Aldrich 
anti-Pias Y goat 1:1000   Santa-Cruz Biotech 
anti-RACK 1 mouse 1:1000 1: 50 1:50 BD  
anti-phospho Smad 1/5/8 rabbit 1:1000   Cell Signaling 
anti-Smad 1/2/3 mouse 1:1000   Santa-Cruz Biotech 
anti-SMA mouse 1:2500 1:300 1:300 Sigma-Aldrich 
anti-Tubulin mouse 1:1000   Santa-Cruz Biotech 
Secondary antibody      
Alexa Fluor 546 anti-rabbit IgG goat   1:250 Molecular Probes 
Alexa Fluor 546 anti-mouse IgG goat   1:250 Molecular Probes 
FITC-conjugated anti-mouse IgG goat   1:300 ZyMax 
FITC-conjugated anti-rabbit IgG goat   1:300 ZyMax 
FITC-conjugated anti-goat IgG rabbit   1:300 ZyMax 
POD-conjugated anti-rabbit IgG 
POD-conjugated anti-goat IgG 
POD-conjugated anti-mouse IgG 
goat 
rabbit 
goat 
1:10000 
1:10000 
1:10000 
  Pierce 
Pierce 
Pierce 
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